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ABSTRACT
Staphylococcus pseudintermedius is the primary cause of canine pyoderma. The vast
majority of S. pseudintermedius are resistant to all antimicrobials available to
veterinarians. Accordingly, there is a need for alternative approaches to control
staphylococcal infections, such as vaccines. Development of vaccines to control
staphylococcal infections is a high priority, however there are no licensed S.
pseudintermedius vaccines. This is likely due to a lack of information about S.
pseudintermedius protein functions, surface accessibility and epitope conservation.
Effective staphylococcal defenses are rooted in the ability of the bacteria to neutralize
and/or destroy important components of their host’s defenses. The objective of this study
was to identify and direct the immune response against the most important antigen

targets. This was achieved using three strategies
(a) Identification and understanding the roles of protein A, leuxotoxin-I, SpEX [S.
pseudintermedius Exotoxin] and 5’ nucleotidase in S. pseudintermedius pathogenesis
and host immune response evasion.
(b) Attenuation of these proteins to make them safe without eliminating epitopes that
induce a protective immune response.
(c) Evaluation the neutralizing effect of specific antibodies developed in clinically health
dogs against these proteins.
In this study, a conserved S. pseudintermedius protein A, leuxotoxin-I, SpEX [S.
pseudintermedius Exotoxin] and 5’ nucleotidase in vitro were characterized and identified
as a critical virulence factors for immune suppression. S. pseudintermedius protein A
binds antibody on bacterial surface preventing destruction of bacteria and serves as
superantigen that destroys B cells and blocks host antibody response. Leukotoxin I kill
host leukocytes preventing innate and adaptive immune response. S. pseudintermedius
Exotoxin kills host leukocytes preventing innate and adaptive immune response and
neutralizes complement. 5’ nucleotidase converts host adenosine tri and mono phosphate
to adenosine which inhibits phagocytosis and bacterial destruction and clearance by
neutrophils.

v

Attenuated immunogenic recombinant proteins expressed from synthetic genes altered
to produce the attenuated proteins. Clinically healthy dogs were used to develop
neutralizing antibodies against the injected attenuated proteins and their native homolog.
By neutralizing surface-bound and extracellular proteins responsible for host
immunosuppression, these mutant proteins may serve as important components of a
multivalent vaccine for prophylaxis of S. pseudintermedius infections.
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CHAPTER 1
INTRODUCTION

1

Introduction and Review of Literature
Staphylococci are common among commensal bacteria that reside on human
skin and mucous membranes and various species of animals

(1).

Differentiating

between coagulase-positive [CPS] and coagulase-negative staphylococci [CNS] is useful
in terms of their medical significance. CPS encompasses S. aureus, S. pseudintermedius,
S. intermedius, S. schleiferi subsp. coagulans, S. hyicus, S. lutrae, S. cornubiensis and
S. delphini and these bacteria were generally considered capable of causing opportunistic
infections in humans and different species of animals (2). CPS-produced bacterial
coagulase is a virulence factor as the enzyme allows the bacteria to induce fibrinogen
conversion to fibrinopeptides and self-polymerizing fibrin

(2). It is regarded as an

important first step in the attachment and adhesion of CPS within the invaded body, which
promotes staphylococcal growth during the early stages of infection. The coagulum later
protects the staphylococci from defensive cell activities. Once infection is established the
expression of another enzyme (staphylokinase) allows the bacteria to escape the fibrinmediated wall that is self-induced. Subsequently, other factors associated with virulence,
such as hyaluronidase (spreading factor), lipase, collagenase, protease, nuclease, and
urease may all play additional roles in staphylococcal infection pathogenesis (3).
Staphylococcus intermedius group [SIG]
Until 2005, Staphylococcus intermedius was thought to be the causative agent of canine
skin infections based on phenotypic traits. However, in recent years, studying the
bacterial genome using molecular typing methods led to the discovery of a novel species,
S. pseudintermedius, in 2005 as the causative agent of canine pyoderma and other skin
infections [7] and Staphylococcus cornubiensis isolated from a human skin infection in
Cornwall, United Kingdom (4).
Phylogenetic analysis grouped S. intermedius, S. pseudintermedius, S. cornubiensis and
S. delphini in the Staphylococcus intermedius group (SIG) where S. cornubiensis is
genomically relative to S. intermedius with a core genome nucleotide identity of 90.2 %
(4) and phenotypically similar to S. pseudintermedius. Traditional phenotypic diagnostic
tests are not reliable for distinct differentiation between SIG isolates and also from other
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staphylococci. There is a combination of biochemical tests that can be used to
differentiate between different species within SIG group (Table 1.1).
Pyrrolidonyl aryalamidase (PYR) can effectively separate the SIG members (PYR
positive) from S. aureus (PYR negative) (5).
Knowledge of the host range aids in the clinical identification of S. pseudintermedius in a
diagnostic setting where S. intermedius is more or less exclusively isolated from pigeons
and S. delphini has been reported to be isolated from dolphins, horses, cattle, mink,
human and not associated with infections in dogs. Due to their similar biochemistry,
molecular typing is the most accurate method to identify the species within the SIG.
Pathogenesis of S. pseudintermedius
S. pseudintermedius is an opportunistic pathogen. It causes disease when the immune
system of the host is compromised or an external skin barrier breach occurs, such as
wounds and surgical procedures or other factors that predispose the host to atopic
dermatitis. S. pseudintermedius is frequently isolated from the nares, mouth, forehead,
groin and anal region of healthy dogs and cats as a common inhabitant of the skin and
mucosa (6).
Recent advances in genome sequencing technology and bioinformatics have added a
wealth of information to our knowledge about proteins produced by S. pseudintermedius.
More than 170 complete genome sequences of S. pseudintermedius have recently been
reported to help analyze the potential for virulence and special host adaptation of this
versatile opportunistic pathogen (7-14). ED99 and HKU10-03 sequence analysis resulted
in the identification of numerous putative virulence factors including luk-I, exotoxins,
protein A and exoenzymes (13, 14).
S. pseudintermedius is a CPS species with numerous virulence factors (Figure 1.1),
some of which are similar to those described for S. aureus (15) such as proteases,
coagulase as well as proteins associated with the surface such as 5’nucleotidase and
protein A. S. pseudintermedius can produce a variety of toxins including leukotoxins,
enterotoxins and other toxins that cause substantial damage to affected host tissue (16,
17).
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Table 1.1 phenotypic characteristics of SIG isolates (4).
Characteristic

S. cornubiensis NW1T

S. intermedius

S. pseudintermedius

S. delphini

DSM 20373

DSM 21284

DSM20771

Pigment

−

−

−

−

Coagulase

+

+

+

+

Clumping factor

−

−

−

−

DNase

+

+

+

−

β-Haemolysin

+

+

+

+

Mannitol

+

+

−

+

Acetoin

−

−

−

−

Pyrrolidonyl

+

+

+

+

Maltose*

−

+

+

+

d-Galactose*

+

+

+

+

Trehalose*

+

+

+

−

Sucrose*

+

+

+

+

fermentation

aryalamidase*

*Data based on VITEK2 GP card (bioMérieux)(4).
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Protein A, 5’nucleotidase, sortase A

LukS, LukF, coagulase, α-hemolysin
β-hemolysin, SpEX

Figure 1.1 Schematic diagram for S. pseudintermedius cell wall and secreted
virulence proteins.
S. pseudintermedius causes hemolysis of rabbit erythrocytes and hot-cold hemolysis of
sheep erythrocytes through α-hemolysin and β-hemolysin (18). The β-hemolysin has high
affinity and is responsible for the characteristic partial zone of hemolysis observed in
sheep blood agars around colonies (18). It also produces
a two-component leukotoxin, luk-I, encoded on polymorphonuclear cells by two cotranscribed genes, lukS and lukF (17). Luk-I is associated with the most prevalent clonal
population, ST71 in Europe, occurring especially methicillin-resistant isolates.
S. pseudintermedius is also capable of binding to fibrinogen, fibronectin and cytokeratin
using surface molecules that act as microbial surface components recognizing adhesive
matrix molecules (MSCRAMM) (15). Proteins associated with the cell wall (CWA), such
as microbial surface

components

that recognize

adhesive

matrix molecules

(MSCRAMMs), play an essential role in bacterial attachment to the extracellular matrix of
the host. In each bacterial species, the repertoire of MSCRAMMs contributes to host
adaptation and survival. S. pseudintermedius CWA proteins have been named as ‘Sps’
5

(S. pseudintermedius surface proteins). In particular, at least 19 CWA proteins are known
as SpsA through SpsR in isolate ED99 (19, 20).
Sortase A is a cysteine transpeptidase enzyme that most Gram-positive bacteria
produce. During pathogenesis, surface proteins play a crucial role in Gram-positive
bacteria. The main function of sortase A is to anchor surface proteins with a C-terminal
LPXTG motif onto the peptidoglycan cell wall. Sortase A anchored proteins act as nutrient
transporters, adhesins, internes, blood clotters and immune evasion factors (21). S.
aureus lacking sortase cannot assemble LPXTG proteins on their surfaces and cannot
form abscess lesions in organs or cause lethal bacteremia in animal models of infection
(22). Sortase A is the prototypical enzyme for class A families and has been studied
extensively. In Firmicutes, Sortase A is present, and responsible for the anchoring of
proteins mediating bacterial adhesion.
In the genome sequences of different S. pseudintermedius isolates that represent the
main clonal populations in the United States, Asia and Europe, a putative srtA gene was
identified. Functional domains were identified on the predicted protein sequence. S.
pseudintermedius Sortase A has amino acid similarity of 57% with S. aureus Sortase A.
Protein A
A number of potential virulence factors, such as cell wall anchored proteins (CWA),
secreted enzymes and toxins, may explain the fitness of staphylococci .These virulence
factors have been more thoroughly investigated and characterized in S. aureus than in S.
pseudintermedius, although the majority have been shown to have similar features. This
is the case of the Staphylococcal protein A (SpA), a 40-60 kDA protein in the most
prevalent group of CWA proteins. In S. aureus, SpA includes five repeated domains (E,
D, A, B and C) (Figure 1.2), each of which binds the Fc region immunoglobulin (Ig) G
with high affinity and the variable heavy VH3 subclass Fab region of Ig. Practically all
clinical S. aureus isolates express and secrete protein A during the exponential growth
phase. Because of its binding activities on human and animal Igs, protein A is
immunosuppressive. Protein A binding to Fc region of IgG blocks opsonophagocytic
killing (OPK), while Fab binding and IgM cross-linking promotes B cell superantigen
activity. In particular, B-cell receptor SpA crosslinking causes an expanding lymphocyte
6

population to proliferate and to collapse while undergoing apoptosis. Together with
century-long studies in staphylococcal vaccines, it was recently shown that immunization
with nontoxigenic protein A (SpAKKAA) allowed infected Guinean pigs to trigger an anti- S.
aureus protective antibody response.
In view of these considerations, Balachandran et al investigated the common
characteristics between S. aureus and S. pseudintermedius protein A to understand if S.
pseudintermedius protein A may be a vaccine candidate. There is little known about S.
pseudintermedius protein A so far. Indeed, Moodley et al. (23) initially described a
putative spa gene in 2009; subsequently, sequencing of the entire genome of S.
pseudintermedius ED99 revealed that two genes had an orthologue conformation with S.
aureus spa, spsP and spsQ. The SpsP protein is composed of a predicted N-terminal
sequence of 33 amino acids and three IgG-binding domains. The C-terminal region has
a predicted X region with a sequence similarity of 63 percent to that of S. aureus. The
spsQ gene, on the other hand, encodes a protein consisting of 462 amino acids with a
predicted N-terminal sequence of 33 amino acids, followed by a repeating region
comprising 4 IgG-binding domains.
The C-terminal region has a predicted X-region that includes a repeat sequence (Xr) of
77 amino acids and a constant region (Xc) with 70% similarity to S. aureus X-region.

S. aureus SpA

Figure 1.2 Schematic diagram for Staphylococcus aureus protein A
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Riley et al. recently reported (9) that the full-length spsQ gene was consistently present
in clinical isolates of S. aureus, while spsP gene was less frequently portrayed by S.
pseudintermedius.
A total of 18 clinical S. pseudintermedius isolates with various lineages were examined
by Balachandran et al. (21) and she showed that the spsQ gene was present in all
isolates, as already observed, but its expression level differed between STs and the
protein A secreted in supernatant. Compared with other sequence types, the difference
was found to be significant for ST71 compared with ST68, and also for these two clones.
These results provide further information on the global success of the two lines, which
are a major challenge in the treatment of MRSP infections nowadays. In general data
about S. pseudintermedius virulence is scarce and there is a need for continuous efforts
to better understand the pathogenicity of this organism. The relationship between dogs
and their owners has dramatically changed during the last decade. Microorganisms are
increasingly transmitted between people and their dogs (24). As was shown by the MDR
ST71, which has been isolated at a higher frequency both in humans and animals. The
risk of MRSP infection is unclear in humans however, evidence is given of potential longterm human MRSP carriage due to the particular adaptive ability of certain MRSP lines,
such as ST71 and ST68, to the human host.
S. pseudintermedius SpsQ is a virulence factor that permits the bacterium to evade the
immune response. SpsQ can bind IgG through its Fc regions to protect staphylococci
from opsonophagocytosis (Figure 1.3). Thus, S. pseudintermedius protein A enables
bacteria to escape opsonization and phagocytosis which results in persistent diseases.
Phagocytosis assays performed by Balachandran (21) also confirmed these results. On
the other hand, several steps towards the immunological aspects of S. aureus SpA have
been made. Modification of the immunoglobulin function by SpA may have impede the
elicitation of antibody-responsive reactions to bacterial envelope elements (CP5/CP8,
ClfA, and IsdB). Virulence contributions of protein A depend on its binding to both Fc and
Fab domains of IgG (Figure 1.3). Incremental defects in systemic infection pathogenesis
were reported in S. aureus spaKK and spaAA variants. In addition, contributions of
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Figure 1.3 Mechanisms of SpA-mediated immune evasion

S. aureus protein A to virulence were not present in mice lacking both mature B cells and
their antibody products.
In contrast to wild-type staphylococci infection, antibodies that neutralize SpA had been
elicited by the immunization of mice or rabbits with an engineered SpA KKAA in which 20
amino acid residues, essential for their combination with IgG Fc and Fab were replaced.
SpAKKAA–derived polyclonal antibodies protect the B cells from SpA, stimulate
staphylococcal phagocytosis and promote humoral immune reactions to a wide range of
antigens. In addition, studies using SpAKKAA monoclonal antibodies (MAb) have confirmed
these observations (25).
leukocidin
The first PVL positive MRSA was seen at the end of 1990 and in recent years it has been
distributed globally (26). The role of PVL in S. aureus virulence and pathogenicity are
under investigation. The pathogenicity of S. aureus is increased by Panton Valentine
leukocidin through necrosis, acceleration of apoptosis and killing of polymorphonuclear
and mononuclear cells (27). Some studies have shown, however, that PVL is not
associated with organism virulence by showing improved clinical outcomes from skin and
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soft tissue infections (28, 29). The role of PVL in clinical results is therefore still under
discussion. The reason for the clinical results in these studies could be determined by the
efficacy of antibiotic therapy. The marker of community-acquired MRSA, responsible for
soft tissue and deep dermal infections, is Panton Valentine leucocidin (30, 31). However,
the overall PVL scenario varies between MRSA isolates. The increasing prevalence of
PVL among MRSA isolates is reported from various countries (32, 33). The prevalence
of PVL among MRSA and MSSA (MRSA: 85.1 and MSSA: 48.8 percent) has been
reported in India, which shows a higher prevalence of PVL in MRSA (34). The PVL
prevalence in other parts of the world has decreased (35-37), reflecting a significant
variation in geographical location and population prevalence, which included 5% in
France, 4.7% in Great Britain, 8.1% in Saudi Arabia and 14.3% in Bangladesh.
A key feature of S. aureus pathogenesis is its capacity to secrete a wide range of immune
evasion factors. These include pore-forming toxins that are of interest in developing new
therapeutic approaches (38). Toxins that form pores are virulence factors that are
expressed as monomeric proteins that are water-soluble. They assemble on the
membranes of the target cells to form a pore after the receptors of their hosts have been
recognized (39). The pore-forming toxins can be classified into two families based on the
secondary structure of the transmembrane region of the pore structure: the -helical family
and the -barrel family. The β-barrel family consists of one member of the pore-forming
toxin single-component, αHL, and three members of the bicomponent pore-forming toxin,
γ-hemolysin (γ-HL), Panton–Valentine leukocidin (PVL) and leukocidin (Luk) (40). Seven
known bicomponent leucocides have been found to date: LukSF-PV, HlgAB, HlgCB,
LukAB/HG, LukED, LukPQ and LukMF (41).
There are two separate water-soluble subunits of the bicomponent pore-forming toxins,
one of class S (slowly-eluted component of PVL) and one of class F (fast-eluted
component of PVL). Recently, the list of host molecules which interact with the
bicomponent pore forming toxins has also included a number of protein receptors, which
greatly enhances the understanding of specific cell targeting by S. aureus (42).
Indeed, for most leukocidins, certain cell membrane lipids are known to bind and even
facilitate the prepore-to-pore transition (43, 44). Typically, the S subunit is involved in
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targeting the specific cell type through interaction with surface receptors and recruiting
the other toxin subunits, resulting in oligomerization and octameric prepore formation.
The prepore consists of alternating S and F subunits and is capable of assembling a barrel pore domain in the cell membrane, producing the mature pore that ultimately
causes osmotic lysis to cause cell death (45).
The complex of mushroom-shaped pore is divided into three domains resembling the
domains of soluble monomers: cap, rim, and stem. The cap is made up of sandwich and
latch domain of each protomer. The rim domain is an open-face sandwich that extends
the cap domain below. The rim is important for the lipid bilayer interaction and the
interaction with specific receptors of the membrane. The stem domain is involved in the
transmembrane-barrel formation in each protomer, which ultimately perforates the
membrane. Secreted water - soluble monomers reveal a similar overall protomer
structure except for the stem region, which is more compact than three antiparallel –
strands stacked with cap domain -strands (46-49).
LukED is one of the key virulence factors that plays a vital role in S. aureus bloodstream
infections as shown by the dramatic attenuation of an isogenic highly virulent
staphylococcal strain with LukED deleted in animal models (50, 51). LukED is also the
only highly neutrophil - defeating leukotoxin (50). LukED targets a wide range of host cell
that has been partially clarified by recent identification of its binding partners (CCR5,
CXCR1 and CXCR2)(50).
LukED can target both innate and adaptive immunities by binding these three cell
receptors. Indeed, among the sequenced S. aureus, LukE and LukD display almost no
sequence diversity (52). In addition, the association of LukED with staphylococcal bullous
impetigo and post-antibiotic diarrhea has been shown (53). These findings identify LukED
as a target for alternative and more effective staphylococcal infection therapy.
In an earlier study, mutants of S. aureus LukS-PV and LukF-PV were rationally designed
to be deficient in oligomerization by Karauzum et al.(54) Testing mutant versions of LukS
- PV with a series of amino acid substitutions, they found LukS - mut9 with T28F / K97A
/ S209A to be highly immunogenic and non - cytototoxic when mixed with LukF - PV [18].
LukS -PV - raised rabbit immunoglobulin reduced the cytotoxic effect of gamma
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hemolysin A and B subunits, gamma hemolysin C and B subunits and LukE and LukD,
and non-canonical pairs gamma hemolysin B subunit and LukE, gamma hemolysin C
subunit and LukD and gamma hemolysin A subunit and LukD (55).
S. pseudintermedius also produces Luk-I leucotoxin, which is very similar to S. aureus
Panton - Valentine leucocidin (PVL) (56, 57). S. pseudintermedius produces a two component leukotoxin, Luk-I, composed of secreted LukS-I and LukF-I proteins that
induce cell lysis.
Ruzauskas et al. (58) isolated S. pseudintermedius from dogs with various diseases and
therefore found genes that encode pathogenic factors. A high frequency (68.8 %) of lukI and/or siet genes was detected in S. pseudintermedius isolated in Lithuania. It is
interesting to note that all isolates that harbored both lukF and lukS genes also harbored
the siet gene (p<0.01), but not vice versa. Such a statistical relationship had not been
detected before to our knowledge. In the study of the association between the presences
of siet gene in isolates from skin infections compared to isolates from other types of
infection, statistically significant results were obtained (58).
Siet gene is primarily found in isolates from skin infections (59), this is consistent with the
fact that exfoliative toxin is a key virulence factor in S. pseudintermedius causing canine
pyoderma. The luk-I genes have been found in various S. pseudintermedius strains
regardless of the source of isolation. Luk-I demonstrates strong leucotoxicity towards
different polymorphonuclear cells (57). By suppressing its cellular immunity, it could be
responsible for the host invasion and could be produced by different S. pseudintermedius
strains.
Maali et al. (60) tested the effect of Luk-I on non-professional phagocytic cells (NPPc)
and no cytotoxic activity was observed with recombinant Luk-I toxin against NPPc
compared to that found for PMN cells. In response to this issue, he conducted an in vitro
trial with promyelocytic U937 cells stably transfected to C5a and CXCR2, which are the
PVL and LukED leucotoxin target receptors. The results indicated that, as previously
reported for S. aureus LukED, Luk-I induces cell death through the CXCR2 receptor
specifically present on immune cells (PMNs, macrophage), explaining the lack of NPPc
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cytotoxicity. This feature is probably related to the high Luk-I and LukED homology (61).
Focused on humans as well as dogs, this receptor is also highly homologous (75 %) (62).
Innate immunity is important in the defense against staphylococcal and neutrophil
migration and represents the first step of the acute inflammatory response toward
infection. This process starts with neutrophils binding to inflamed endothelium, migration
toward a site of inflammation, followed by phagocytosis of infectious organisms. It is
largely dependent on integrin molecules in the neutrophil membrane binding to
endothelial receptors (63) and phagocytosis is enhanced by opsinins.
S. pseudintermedius exotoxin protein
Staphylococcal SSLs are two- domain secreted proteins with an average size of 25 kDa
(64,

65).

The

first

domain,

located

at

the

N-terminus,

displays

an

oligosaccharide/oligonucleotide binding (OB) fold forming a β- barrel. The second domain
possess a β-grasp motif that consists of a twisted β-sheet of four to five antiparallel
strands, located at the C-terminus. The two domains are separated by a structurally
conserved α-helix. Tuffs et al., (66) showed that staphylococcal enterotoxin-like toxin
(SEIX) secreted by S. aureus shares their domain structure with SSLs. SSLs target innate
immunity components through different mechanisms such as complement binding but do
not bind to T cell receptors or the major histocompatibility complex. SEIX exerts the same
function, however, it exhibits a superantigen effect via its oligosaccharide/oligonucleotide
binding (OB) fold on T cells (66, 67).
In previous studies, SSL4 (67), SSL5 (65) and SSL11 (65), were found to target myeloid
cells and interfere with neutrophil migration through their sialated glycans-binding site in
the C- terminal β-grasp domain. Chung et al., (68) showed that SSL11 with a single site
mutation, T168P, had defective binding compared to native SSL11 and lost its inhibitory
effect on neutrophil attachment to P-selectin. The OB fold domain of SSL7 binds to the
IgA Fc region while the β-grasp motif adheres tightly to complement component C5
resulting in inhibiting of complement mediated hemolytic activity (65). SSLs are not
associated with cytotoxic activity.
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S. pseudintermedius 5-nucleotidase
Upon infection or cell damage, high amounts of adenosine triphosphate (ATP), adenosine
monophosphate (AMP), adenosine diphosphate (ADP) are released from damaged cells,
which serve as mediators of inflammation through purinergic cell surface receptor
signaling (69, 70). As a control mechanism to prevent excessive damage to host tissue,
adenosine counteracts the effect of ATP by stimulation of adenosine receptors
suppressing the pro-inflammatory response. Four adenosine receptors have been
described: A1R, A2aR, A2bR and A3R. Neutrophils express all four adenosine receptors
(71, 72). They are the most abundant mammalian leukocytes and form an important
component of the innate immune response against staphylococcal infection (73, 74).
In mammals, extracellular nucleotide and adenosine concentrations are controlled by
nucleotide metabolizing enzymes. In this two-step process, CD39 catalyzes
dephosphorylation of ATP and ADP to produce AMP. 5′-nucleotidase (CD73) contains a
characteristic two-signature sequence domain and hydrolyzes AMP into adenosine (74,
75). Some bacilli employ adenosine synthase to interfere with the balance between
extracellular nucleotides and adenosine by perturbing the adenosine level beyond the
physiological range (76, 77). Extracellular 5′-nucleotidases have been identified in S.
aureus and Streptococcus suis type 2 (75, 78) and shown to play an important role in
evasion of the innate immune response.
Thammavongsa et al, (75) showed that S. aureus can escape phagocytic clearance in
blood and identified adenosine synthase A (AdsA), a cell wall–anchored enzyme that
converts adenosine mono- and tri-phosphate to adenosine, as a critical virulence factor.
Staphylococcal synthesis of adenosine in blood, escape from phagocytic clearance, and
subsequent formation of organ abscesses were all found to be dependent on AdsA. They
observed further that AdsA-deficient S. aureus were cleared more rapidly from the
bloodstream of BALB/c mice than wild-type staphylococci, correlating with reduced ability
to grow during infection and/or seed abscesses. Furthermore, adenosine attenuates
neutrophil antibacterial activity by suppressing the production of superoxide and nitric
oxide both of which are integral to the killing of phagocytosed bacteria (72, 75).
S. aureus AdsA has critical residues (Asp127 and His129) for divalent metal cation
binding located in the first nucleotidase signature sequence (ILHTNDIHGRL) (75) The
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essential amino acids for catalytic activities of AdsA, His196 and Asp199, represent the
catalytic

Asp-His

dyad and

are

located

in

the

second

signature

sequence

(YDAMAVGNHEFD) (75).
Adenosine synthase activity has not been previously described in S. pseudintermedius or
any members of the Staphylococcus intermedius group.
S. pseudintermedius is the primary cause of canine pyoderma (skin infection). Pyoderma
is the most common canine dermatologic disease and the organism is also associated
with urinary tract infections, wound and surgical site infections, external ear otitis, abscess
formation, mastitis and endocarditis. As many as 30-40% of the S. pseudintermedius
isolates tested in clinical laboratories in some geographical regions are methicillinresistant (MRSP). These bacteria are resistant to all β-lactam antibiotics. The vast
majority of MRSP are also resistant to other clinically useful antibiotics and an increasing
number of MRSP are resistant to all antimicrobials available to veterinarians. Accordingly,
there is a need for immunogenic compositions capable of inducing antibodies to, and/or
a protective immune response to S. pseudintermedius.
S. pseudintermedius Vaccine Development
Development of vaccines to control staphylococcal infections is a high priority, however
there are no licensed S. pseudintermedius vaccines. This is likely due to a lack of
information about S. pseudintermedius protein functions, surface accessibility and
epitope conservation. Information about other species of bacteria, especially
staphylococci, is useful in the development of a S. pseudintermedius vaccine, however,
this species is unique with regard to its disease presentation, genetic structure and
composition, host range, and the virulence proteins it produces. Whole bacterial
staphylococcal vaccines have not been efficacious. With an estimated greater than 2,000
different proteins produced by each bacterium, it is essential to identify and direct the
immune response against the most important antigen targets. However, many of these
proteins are potentially harmful to animals and must be attenuated to make them safe
without eliminating epitopes that induce a protective immune response. Effective
staphylococcal defenses are rooted in the ability of the bacteria to neutralize and/or
destroy important components of the immune system of their hosts.
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This dissertation is organized in a manuscript format. Each chapter is a manuscript.
Chapter 1 is Introduction and literature of review. Chapter 2 characterize recombinant
wild-type and nontoxigenic protein A from S. pseudintermedius that have been previously
published in Virulence Journal. In Chapter 3, a leucocidin produced by S.
pseudintermedius has been identified and characterized and published in PLOS One
Journal. The first whole-genome sequences for S. pseudintermedius Type Strain LMG
22219 (=ON 86T = CCUG 49543T) are presented in Chapter 4 and were published in
Microbiology Resource Announcements (MRA), an online-only, fully open access journal
that publishes articles announcing the availability of any microbiological resource
deposited in a repository available to the community. In Chapter 5, SpEX produced by S.
pseudintermedius has been identified and characterized. In Chapter 6, 5’ nucleotidase
produced by S. pseudintermedius has been identified and characterized. Conclusion and
Recommendations in Chapter 7.
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CHAPTER 2
CHARACTERIZATION OF RECOMBINANT WILD-TYPE AND
NONTOXIGENIC PROTEIN A FROM STAPHYLOCOCCUS
PSEUDINTERMEDIUS
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A version of this chapter was originally published by Mohamed A. Abouelkhair, David A.
Bemis, Stephen A. Kania:

Abouelkhair MA, Bemis DA, Kania SA. 2018. Characterization of recombinant wildtype and nontoxigenic protein A from S. pseudintermedius. Virulence 9:1050-1061

No revisions were made to the original published manuscript beyond general formatting
to allow consistency through the dissertation. My contributions to this paper include: (i)
selection of isolates (ii) experimental design and set up (iii) experimental testing (iv)
data analysis (v) gathering and review of literature (vi) formulation of discussion topics
(vi) writing.
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Abstract
S. pseudintermedius is an opportunistic pathogen that is the major cause of pyoderma
affecting dogs. Conventional antimicrobial treatment for infections caused by this
organism have failed in recent years due to widespread resistance and alternative
treatment strategies are a high priority. Protein A encoded in Staphylococcus aureus by
spa protects the bacterium by binding IgG and acts as a superantigen. S.
pseudintermedius possess two genes orthologous to S. aureus spa, spsP, and spsQ. The
purpose of this study was to clone and express SpsQ and SpsQ-M, a non-toxigenic SpsQ,
measure their cytotoxic effect on canine B cells and to evaluate antibody raised against
them in clinically healthy dogs. S. pseudintermedius SpsQ induced apoptosis of canine
B cells. Specific amino acid substitutions diminished SpsQ-M binding to immunoglobulin
and its super-antigenic activity, while its antigenicity was maintained. This recombinant,
non-toxigenic S. pseudintermedius SpsQ stimulated the production of antibodies in dogs
that specifically reacted with SpsQ and greatly diminished its cytotoxic effect on canine B
cells. These results suggest that attenuated SpsQ produced in this study is a good
candidate for inclusion in a vaccine for use in the treatment and prevention of S.
pseudintermedius infections.
Keywords: Protein A, SpsQ, S. pseudintermedius, B cells, immune evasion, virulence,
vaccine
Introduction
S. pseudintermedius, a gram-positive, coagulase-positive bacterium, is commonly found
on the normal skin and nasal flora of household pets (19, 79). It is the major cause of
canine skin and ear infections (19, 80). Furthermore, human infections are sporadically
reported (24, 81), suggesting that, although it is estimated to be low, there is a threat of
zoonotic disease. Approximately 30-35% of the S. pseudintermedius isolates tested in
our University of Tennessee College of Veterinary Medicine Clinical Bacteriology
Laboratory are methicillin-resistant. Methicillin resistant S. pseudintermedius (MRSP) are
resistant to most antimicrobial agents accessible at present and the number of multidrug
resistant staphylococcal isolates is increasing (82-85).
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Alternative approaches to antimicrobial therapy to treat staphylococcal infections, such
as vaccines, have been difficult to develop. This is likely rooted in the ability of the bacteria
to evade and/or destroy important components of their host defenses (86, 87). Protein A
is anchored on the peptidoglycan cell wall and is also secreted during the exponential
growth phase (88-91). It is an important virulence factor, able to bind IgG via its Fc region
(21, 92, 93) protecting staphylococci from opsonophagocytosis. It also binds to and
crosslinks the VH3-family of immunoglobulin idiotypes (the Ig fragment responsible for
antigen recognition), triggering apoptosis (94, 95). Consequently, protein A plays an
important role in enhancing pathogenicity of staphylococci by impairing the development
of the host immune response (25, 86). Recently, it has been demonstrated that
immunization with nontoxigenic S. aureus protein A (SpAKKAA) (with amino acid
substitutions in five repeated domains, E, D, A, B, and C) protected guinea pigs in
experimental models of S. aureus infection (96). Also, S. aureus expressing the mutant
variant was deficient in abscess formation, and laboratory animals infected with these
mutant bacteria overcame the immunosuppressive effects of protein A and developed
adaptive immune responses (96). Likewise, Pankey et al. (97) investigated the use of S.
aureus protein A (SpA) as a vaccine for bovine mastitis with promising results.
In vertebrates, the immunoglobulin variable region of the heavy chain (VH) is encoded by
diverse genes and the VH differ in length and amino acid composition between species
and each species has it is own repertoire (98-100). In dogs, the VH1-family of
immunoglobulin idiotypes represent the largest portion of VH genes in B cell populations
(99).
Previous studies on SpA (101) have demonstrated that SpA binds to the Fab portion of
VH3-type IgM on the surface of B cells resulting in cross-linking of B cell receptors that
lead to B cell clonal expansion and subsequent apoptotic collapse, thereby limiting the
ability of the host to produce antibody to other staphylococcal antigens (25).
In 2011, Bannoehr et al. (20) found that S. pseudintermedius possess two genes
orthologous to S. aureus spa, spsP (encoding SpsP) and spsQ (encoding SpsQ,
analogous to SpA). Balachandran et al. (21) recently found that SpsP and SpsQ consist
of approximately 377 and 462 amino acids, respectively. Both proteins have predicted N20

terminal sequences of 33 amino acids, followed by a repeat region of three or four IgGbinding domains and a C terminal region that shares about 63% sequence similarity to
the X-region of S. aureus.
The Immunoglobulin-binding domains (IgBDs) are highly conserved between SpsP and
SpsQ, with amino acid sequence identity ranging from 67% to 90%. Balachandran et al.
(21) found that spsQ was present in all clinical isolates of S. pseudintermedius tested
within diverse multilocus sequence types, although they had different levels of
expression, whereas spsP was less conserved and often occurs in degenerate form. They
showed that S. pseudintermedius SpsQ is cell wall anchored and was detected in the
bacterial secretome during log phase (21).
SpsQ bound to canine IgG primarily via its Fc region (21). This interaction was inhibited
by anti-SpA raised in chickens which made S. pseudintermedius more susceptible to
phagocytosis (21). Grandolfo (102) suggested that S. pseudintermedius SpsQ could be
considered a possible vaccine target, however, information about SpsQ is scarce and it
is necessary to determine if there are toxic effects of S. pseudintermedius protein A on
canine B cells that can be neutralized with antibody.
The purpose of this study was to characterize the cytotoxic effect of recombinant S.
pseudintermedius SpsQ on dog B cells, develop attenuated SpsQ (SpsQ-M), and
evaluate antibody raised against SpsQ-M in clinically healthy dogs. S. pseudintermedius
SpsQ-M was tested for its antigenicity and B cell killing. The results from this study
suggest that S. pseudintermedius SpsQ may serve as a key component in a vaccine or
as part of an immunotherapeutic treatment.
Results
Bioinformatics Analysis and S. pseudintermedius Protein A characteristics
S. pseudintermedius ED99, representing isolate that expresses both SpsQ and SpsP,
SpsQ contained four and SpsP had genes encoding a maximum of three Ig-binding
domains (Figure 2.1, a). This compares to five domains with AA identities of 74% in
Staphylococcus aureus subsp. aureus strain Newman SpA (Figure 2.1, b). Three out of
four SpsQ domains share 84-88% identity with the C domain of S. aureus SpA with
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threonine at position 19, while only one domain is more similar to the B domain of S.
aureus SpA (Figure 2.1, c).
Multiple sequence alignment (MSA) between each domain of SpsQ and domain C of SpA,
the most similar domain to SpsQ IgBDs, showed that each domain in SpsQ has binding
sites for the IgG Fcγ (Glutamine (Q) 5 and Q 6), and Fab region (aspartate (D) 32 and D33)
of surface membrane-associated variable heavy 1 (VH1)-encoded B cell antigen
receptors (Figure 2.1, c). Furthermore, as with SpA of S. aureus, the secondary structure
of SpsQ consists only of alpha helices and each Ig binding domain consists of three
helices (Figure 2.1, d).

Figure 2.1 S. pseudintermedius SpsQ characteristics and basis for generation of
recombinant nontoxigenic protein A (SpsQ)
(a)

Pairwise alignment between S. pseudintermedius ED99 SpsQ and SpsP.
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S. aureus SpA

S. pseudintermedius
SpsQ
442 A.A

Figure 2.1 (b) SpA of S. aureus and SpsQ of S. pseudintermedius harbors an N-terminal
signal peptide (orange boxes), Ig binding domains, variable region X (grey boxes), LysM
sequence (green boxes) and C-terminal sorting signal (black boxes).

Figure 2.1 (c) Amino acid sequence of the four Ig binding domains, as well as Ig binding
domain C of SpA, with the position glutamine (Q, highlighted in blue) 5 and 6 and
aspartate (D, blue highlight) 32 and 33 as indicated.
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Figure 2.1 (d) SpsQ Secondary structure composition
Cloning, expression, and purification of recombinant SpsQ and SpsQ-M
Recombinant polyhistidine tagged SpsQ and SpsQ-M were produced in E. coli and
purified using HisPur Ni-NTA resin under native conditions and eluted using an imidazole
gradient. The molecular weights of SpsQ and SpsQ-M determined in western blots were
of the expected sizes (47.2 and 47.6 kDa, respectively) (Figure 2.2).
Antigenicity of SpsQ and SpsQ-M and their reactivity with serum from a dog with
pyoderma
Chicken anti-protein A, chosen because protein A does not bind chicken immunoglobulin,
had strong reactivity with affinity-purified SpsQ-M similar to that with S. aureus SpA and
S. pseudintermedius SpsQ, indicating the attenuated protein retained its antigenicity
(Figure 2.3).
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Figure 2.2 Western blot of recombinant S. pseudintermedius wild and mutant
protein A with HRP-conjugated anti-6xhis tag monoclonal antibody, SpsQ and
SpsQ-M were expressed in E. coli with M.W. of 47.2 and 47.6 KDa, respectively.
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Figure 2.3 ELISA assay measuring the reactivity of HRP- conjugated chicken antiprotein A antibody with recombinant SpsQ, SpsQ-M and commercial S. aureus SpA
coated on ELISA plates
The values represent average from three independent experiments. (*P < 0.05 was
considered significant). ns – Not significant. There was no statistically significant
difference between any sample P >0.05 (ns).
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Sera from a dog with a history of chronic pyoderma showed significantly lower reactivity
against SpsQ-M (Figure 2.4 a) compared to recombinant wild-type SpsQ and SpA. SpsQM had significantly lower binding (p-value of 0.0001) to commercial dog IgG (Figure 2.4
a), IgM (p-value of 0.0001) (Figure 2.4 b) or IgA (p-value of 0.0001) compared to SpsQ
and SpA. (Figure 2.4 c).
S. pseudintermedius protein A induced apoptosis of canine B cells
Affinity-purified SpsQ-M had a low apoptotic effect on B cells at 1.5 h in contrast to
recombinant SpsQ at the same time point, with a mean +/- SEM fluorescent intensity
(MFI) difference of 2052 ± 285.2 between SpsQ and SpsQ-M (p-value of 0.0063) (Figure
2.5, a). Incubation of the cells for 3.5 h with SpsQ-M resulted in a Sytox MFI reduction of
519,065 ± 128,292 SEM compared to that of SpsQ (p-value of 0.0003) (Figure 2.5, b).
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Figure 2.4 Infection with S. pseudintermedius did not elicit antibody specifically
reactive with Staphylococcal protein A (a) S. aureus SpA and S. pseudintermedius
recombinant SpsQ and SpsQ-M were coated on ELISA plates at 2 µg/ml in PBS. Then
were incubated with serum from a dog with chronic pyoderma at a dilution of 1:2000, dog
whole IgG molecule was used at the same dilution for comparison to measure nonspecific IgG binding. Bound IgG were detected by HRP- Goat anti-dog IgG heavy and
light chain. S. aureus SpA and S. pseudintermedius SpsQ reacted with both whole dog
serum with chronic pyoderma and commercial canine IgG fraction with no significant
difference (ns), however, attenuated SpsQ had significantly reduced nonspecific binding
to both whole canine serum and canine IgG fraction (p value <0.0001) ****.
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Figure 2.4 (b) S. aureus SpA and S. pseudintermedius SpsQ and SpsQ-M were coated
on ELISA plates at 2 µg/ml in PBS. Then were incubated with serum from a dog with
chronic pyoderma at a dilution of 1:2000. Bound IgM were detected by HRP-Goat antidog Goat anti-dog IgM µ chain.
Recombinant SpA and SpsQ bind to IgM from dog with pyoderma with no significant
difference (ns) However, SpsQ-M significantly reduced nonspecific binding to IgM in dog
serum (p value =0.0001) ****. The values represent average from three independent
experiments. (*P < 0.05 was considered significant). ns – Not significant.
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Figure 2.4 (c) SpA, SpsQ and SpsQ-M were coated on ELISA plates at 2 µg/ml in PBS.
Then were incubated with serum from a dog with chronic pyoderma at a dilution of 1:2000.
Bound IgA were detected by HRP-Goat anti-dog Goat anti-dog IgA. Recombinant SpA
and SpsQ bind to IgA from dog with pyoderma with no significant difference (ns) However,
SpsQ-M significantly reduced nonspecific binding to IgA in dog serum (p value <0.0001)
****. The values represent average from three independent experiments. (*P < 0.05 was
considered significant). ns – Not significant.
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Figure 2.5 S. pseudintermedius recombinant SpsQ has a superantigenic effect on
canine B cells (a) Gating on canine B cells using PE-anti-CD21 antibody, we found SpsQ
induced B cells apopstosis after 1.5 hr (red peak on histogram) compared to SpsQ-M
(violet peak on histogram). Mean Fluorescent Intensity (MFI) of blank, SpsQ and SpsQM relative to SpA was calculated based on average values from three independent
experiments. (*P < 0.05 was considered significant). ns – Not significant. There was no
statistically significant difference between SpA and SpsQ MFI after 1.5, P >0.05.
However, MFI of SpsQ-M was significantly lower with P=0.0063 **.
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Figure 2.5 (b) Gating on canine B cells using PE-anti-CD21 antibody, we found SpsQ,
with longer incubation for 3.5 hr, killed B cells (brown peak) compared to SpsQ-M (yellow
peak) on histogram. MFI% of blank, SpsQ and SpsQ-M relative to SpA was calculated
based on average values from three independent experiments. (*P < 0.05 was considered
significant). ns – Not significant. There was no statistically significant difference between
SpA and SpsQ MFI after 3.5 hr, P >0.05. However, MFI of SpsQ-M was significantly lower
with P=0.0003***.
Specific antibody responses in dogs that reduce the effect of SpsQ on B cells in
vitro
ELISA analysis of sera obtained from dogs on days -7, 8, 15 and 29 (relative to
injections) showed that antibodies against S. pseudintermedius SpsQ-M and SpsQ were
detected on day 15 and reached the highest level on day 29 (P = 0.0001) compared to
pre-injection control sera (Figure 2.6 a, b).
Pre-incubation of SpsQ, at a concentration of 100 µg/ml in PBS with dog anti-SpsQ-M
resulted in 105665 ± 900.3 SEM, n=1 reduction in annexin mean fluorescent intensity
(MFI) as compared with that of SpsQ treatment alone (Figure 2.7).
Discussion
Protective host immune responses against extracellular pathogens are typically antibodymediated. Unfortunately, staphylococcal infection does not usually establish protective
immunity (98, 103-105) and efficacious staphylococcal vaccines have proven difficult to
develop. Most vaccine research has focused on
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Figure 2.6 (a,b) Dog injected with SpsQ-M developed specific IgG reactive with
native and mutant protein A
Specific antibodies against S. pseudintermedius SpsQ-M (a) and SpsQ (b) were detected
using an indirect ELISA after the second injection (on day 15) and were higher on day 29
(p = 0.0001) compared to pre-injection control sera.

(a)
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(c)

Figure 2.7. Dog anti- SpsQ-M antibody protects canine B cells from the
superantigenic effects of SpsQ. Pre-incubation of SpsQ with dog anti-SpsQ-M resulted
in mean 105,665 ± 900.3 SEM, n = 1 reduction in mean fluorescent intensity (MFI) from
SpsQ on canine B cells compared to that of SpsQ treatment alone. (a) Gating on canine
peripheral blood mononuclear cells (PBMC) based on side and forward scatter (shown in
dot plot) and (b) on B cells using PE-anti-CD21 antibody (shown in density plot). (c) SpsQ
induced B cell apopstosis after 1.5 hr (red peak on histogram) compared to SpsQ
preincubated with dog serum at dilution 1:100 (blue peak on histogram).
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S. aureus, which most commonly affects humans and is distinguished from S.
pseudintermedius, which is primarily of veterinary concern.
Two forms of S. pseudintermedius protein A contain IgBDs that are similar to each other
and likely to be antigenically cross-reactive. Because of their similarity and the presence
of SpsQ in all tested isolates, SpsQ was used for this study. Understanding how S.
pseudintermedius subverts the canine immune response is important for vaccine
development and to facilitate natural host humoral immunity.
S. pseudintermedius SpsQ binding with the Fab region of surface membrane-associated
VH1-encoded B-cell antigen receptors induce apoptosis in canine B cells. We developed
a non-toxigenic SpsQ (SpsQ-M) by substitution of residues responsible for dual reactivity
of each SpsQ domain with IgG Fcγ and Fab regions of surface membrane-associated
VH1-encoded B-cell antigen receptors. Compared to staphylococcal protein A (106),
SpsQ-M had much lower reactivity with IgG. Moreover, IgG, IgM, and IgA in sera from a
dog with a history of chronic pyoderma had little immune-mediated binding to SpsQ-M
indicating a lack of natural production of antibody elicited by infection with S.
pseudintermedius. Comparing purified recombinant wild-type and mutant SpsQ, we found
SpsQ-M had a significantly lower toxic effect on canine B lymphocytes. These results are
in agreement with the findings of Kim et al (25) with S. aureus SpA (KKAA) as determined
using mouse B lymphocytes and human immunoglobulins.
It should be noted that specific antibody directed against native protein A cannot be
measured due to the non-immune binding of protein A to immunoglobulin. After injecting
a clinically healthy dog with SpsQ-M, we observed a high titer of SpsQ-specific antibodies
in agreement with Kim et al findings with SpAKKAA injected in mice (25). These results
indicate that SpsQ, similar to SpA, suppresses adaptive immune responses during
staphylococcal infection which may explain why previous S. pseudintermedius infections
are not associated with protective immunity against recurrent infection.
Dog anti-SpsQ-M abolished the superantigenic effect of SpsQ that triggers apoptotic cell
death in canine B cells, consistent with the findings of others with SpA studied in noncanine systems (25).
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Collectively, the use of SpsQ-M will improve our understanding of the immune interactions
between S. pseudintermedius and the dog. Data presented in our study suggest that
blocking the Fcγ and Fab binding activities of SpsQ could be an alternative or adjunct to
conventional antimicrobial treatments for infections caused by S. pseudintermedius
including canine pyoderma (87). Canine anti-SpsQ-M may reduce SpsQ immune
suppression in dogs, stimulate the production of specific antibodies against S.
pseudintermedius and establish a protective immunity against recurrent infection. A
SpsQ-M vaccine would likely contain additional S. pseudintermedius virulence factors.
Material and Methods
Ethics Statement. Experimental protocols were reviewed and approved by the University
of Tennessee Institutional Animal Care and Use Committee (IACUC) including obtaining
blood samples of dog (2474-0716) and injecting dogs with recombinant protein for
producing antibodies (2572-1217).
Bioinformatics Analysis
MSA of spsQ from diverse isolates of S. pseudintermedius (n=100), was performed using
Geneious, version 9.1.3(107). The bacterial localization prediction tool, PSORTb version
3.0.2 (http://www.psort.org/psortb/ )(108), was used to determine the topology and
domain structure of SpsQ and SpsP. SpsQ modeling and binding site prediction were
performed using Protein Homology/analogY Recognition Engine V 2.0 (Phyre 2)
(http://www.sbg.bio.ic.ac.uk/phyre2)

(109),

and

the

3DLigandSite

(http://www.sbg.bio.ic.ac.uk/3dligandsite/ ) (110), using SpA as a basis to predict the
IgBDs in each domain. A pairwise sequence alignment of SpsQ and SpsP was used to
identify conserved amino acids critical for IgG Fc and B cell receptor binding.
Identification of IgBDs was guided by S. aureus SpA secondary structure (111) and based
on S. aureus SpA residues (25) responsible for dual reactivity of each domain in SpA
with Fcγ (112) and Fab (113) and shared by S. pseudintermedius SpsQ.
Geneious, version 9.1.3 was used to select the locations for amino acids to be substituted
in each IgBD and to design a full-length, four domains (SpsQ-M) attenuated S.
pseudintermedius protein A construct (SpsQ-M). Glutamine (Q) 5 and 6, as well as
aspartate (D) 32 and 33 in each domain of SpsQ were selected as critical amino acids for
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the association of SpsQ with immunoglobulin. To test this, substitutions of Q5K (lysine),
Q6K, D32A (alanine), and D33A were introduced into each IgBDs of SpsQ.
Bacterial strains and growth conditions
The S. pseudintermedius strain used in this study, strain 06-3228 (9), was isolated at the
University of Tennessee, College of Veterinary Medicine Bacteriology Laboratory. It
represents the most common multilocus sequence type (ST) previously reported in the
United States (ST68) (82, 84, 114). Bacterial colonies grown on blood agar plates were
inoculated into 5ml of sterile trypticase soy broth (TSB) (BD Biosciences, San Jose, CA,
USA Cat No. RS1-011-21) and incubated overnight at 37°C with shaking at 225 rpm
(Excella E24 Incubator Shaker, New Brunswick Scientific). Fifty microliters of overnight
culture were inoculated into 5ml of fresh, sterile TSB to initiate log-phase bacterial
cultures. Bacteria were grown at 37°C with shaking at 225rpm until an optical density of
OD 600 = 0.4-0.6 was reached (115).
Cloning, expression, and purification of recombinant wild-type and non-toxigenic
S. pseudintermedius SpsQ
Bacteria from a single colony of S. pseudintermedius strain 06-3228 obtained from blood
agar plates were grown in TSB at 37°C with 225 rpm shaking. DNA was extracted using
a MO BIO UltraClean® Microbial DNA Isolation Kit (QIAGEN Inc., USA Cat No.1222450) according to the instructions of the manufacturer. Oligonucleotide primers (Integrated
DNA Technology, Coralville, USA) (Table 2.1) were designed using a PrimerQuest Tool
(https://www.idtdna.com/Primerquest/Home/Index)

based

on

the

whole

genomic

sequence of S. pseudintermedius strain 06-3228 determined by Riley et al.(9).
The spsQ open reading frame (ORF) without the regions encoding the predicted Nterminal signal peptide was amplified from S. pseudintermedius 06-3228 genomic DNA.
The ORF of spsQ-M was amplified from a PMA-SpsQ-M plasmid (Table 2.2) (Life
Technologies Corp., Carlsbad, CA, USA), containing a synthetic spsQ-M gene. PCR was
performed using taq polymerase (rTaq, Takara, USA Cat No. R004) and the following
cycling conditions were performed: initial denaturation at 95°C for 90 seconds, 30 cycles
of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension
at 72°C for 1 minute followed by a final extension at 72°C for 5 minutes. All ORFs were
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Table 2.1: Primers used to amplify recombinant wild and attenuated protein A
(SpsQ) from Staphylococcus pseudintermedius.

Native full length
spsQ forward

GCATGAGGATCCAAGTTTCGCAGAAGAAGGAGATA

Native full length
spsQ reverse

GCATGAGCGGCCGCACCGAATAATGCCATATCGTTT

Attenuated full
length spsQ
forward

GCATGAGGATCCAAGTTTCGCAGAAGAAGGAGATA

Attenuated full
length spsQ
reverse

GCATGAGCGGCCGCACCGAATAATGCCATATCGTTT

Table 2.2 Plasmids and competent cells used to clone and express recombinant
wild and attenuated protein A (SpsQ) from Staphylococcus pseudintermedius.

Plasmid/ Bacteria

Expressed Gene

Source

PMA-spsQ-M

Contain attenuated full length
S. pseudintermedius protein
A(SpsQ-M)

Synthetic gene, Life
Technologies Corp.,
Carlsbad, CA

pETBlue-2

SpsQ and SpsQ-M expression
Novagen, Madison, WI
with blue/white screening and Cterminal HSV•Tag® and
His•Tag® sequences

Dh5-alpha

Cloning and recombinant SpsQ
and SpsQ-M protein expression

Tuner™(DE3)
pLacI

Novagen, Madison, WI
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amplified without a 6x histidine tag because pETBlue-2 (Table 2.2) allowed T7lac
promoter-based expression of target genes with C-terminal histidine •Tag® sequences.
PCR products were Sanger sequenced at The University of Tennessee Genomics Core
facility.
To clone full length S. pseudintermedius spsQ and spsQ-M, the PCR products were
digested with NotI and BamHI, then ligated into pETBlue-2, an expression vector with Cterminal HSV•Tag® and His•Tag® sequences (Novagen, USA Cat No .70674). The
pETBlue-2 construct transformed into DH5-alpha E. coli chemically-competent cells
(Table 2.2) (New England BioLabs Inc., USA Cat No .C2987I) by heat shock and DH5alpha bacteria were plated on LB agar plates with 100 µg/mL ampicillin. The plasmid
constructs were transformed into Tuner ™ (DE3) pLacI E. coli chemically-competent cells
(Table 2.2) (Novagen, USA Cat No .70623) by heat shock and the bacteria were plated
on LB agar containing 50µg/ml ampicillin and 20µg/ml chloramphenicol.
To express recombinant protein, a single colony of Tuner ™ (DE3) pLacI E. coli was
inoculated into LB broth containing 50µg/ml ampicillin and 20µg/ml chloramphenicol and
bacteria were grown overnight at 37ºC with 225 rpm shaking. LB broth containing 50µg/ml
ampicillin and 20µg/ml chloramphenicol was inoculated with a 1:100 dilution of overnight
culture and grown at 37ºC with 225 rpm shaking until a 600 nm optical density between
0.4 and 0.6 was reached. Protein expression was induced by addition of 1 mM Isopropyl
β-D-1-thiogalactopyranoside (IPTG) (Teknova, USA Cat. No. I3431) and bacteria were
grown for 4 h at 30ºC with shaking at 225 rpm. Bacterial cultures were centrifuged at
12,000 x g for 5 min in 5 ml of protein extraction reagent (BugBuster, Novagen , USA Cat
No. 70584) and 20 µl of 100X protease inhibitor (Cocktail Set III, EDTA-Free Calbiochem,
USA Cat No. 539134), and subsequently incubated for 30 min at 37ºC in a shaking
incubator at 225 rpm. Bacteria were pelleted by centrifugation at 12,000 x g for 45 min at
4°C. Recombinant protein was purified from the supernatant using affinity purification
(HisPur™ Ni-NTA Spin Purification Kit, Thermo Scientific, USA Cat No. 88228). Protein
concentrations were determined using a bicinchoninic acid (BCA) assay (Thermo
Scientific, USA Cat No.23227).
35

Production of antibodies against recombinant proteins
Recombinant SpsQ-M at 100 µg/ 0.5 cc in phosphate buffered saline (PBS) (pH 7.2) was
injected in the lateral thorax by the subcutaneous route, into three clinically normal dogs.
Injections were given once every 7 days for a total of three injections with a control dog
receiving PBS (pH 7.2) only. Blood (6 cc) was collected from a jugular vein using a 20 g
needle and 12 cc syringe 4 times, on days -7, 8, 15 and 29. The collected blood was left
undisturbed at room temperature for 30 min followed by centrifugation at 2,000 x g for 10
min in a refrigerated centrifuge.
SDS-PAGE and western blots
Protein samples were resolved by SDS-PAGE in 4-12 % polyacrylamide gels (Invitrogen,
USA Cat No.

NP0322BOX) and electrophoretically transferred onto nitrocellulose

membranes (Thermo Scientific, USA Cat No. 77010). The blots were blocked overnight
in 5% (w/v) nonfat dried milk powder dissolved in phosphate buffered saline containing
0.05% polyethylene glycol sorbitan monolaurate (Tween 20) (PBS-T) at 4°C. The blocked
membranes were incubated with a 1:2,000 dilution of horseradish peroxidase (HRP)conjugated anti-6xhis tag monoclonal antibody (Thermo Scientific, USA Cat No. MA121315-HRP) in 0.05% PBS-T for 1 h with 225 rpm shaking at room temperature. After
five washes with 0.05% PBS-T, bound antibodies were detected using 1-Step™
chloronaphthol substrate solution (Thermo Scientific, USA Cat No. 34012).
Enzyme-linked immunosorbent assay
For measurement of the antigenicity of recombinant proteins, affinity-purified SpsQ and
SpsQ-M were coated on ELISA plates (Corning, USA Cat No. 3590) at 2 µg/ml in PBS
(pH 7.2). The plates were washed with PBS-T and incubated with HRP- chicken antiprotein A antibody (Gallus Immunotech, USA Cat No. APA) for 1 h at 37°C, then washed.
For this and all subsequent ELISA assays, plates were washed three times with PBS-T
between all incubations, bound antibodies were detected using TMB substrate (Thermo
Scientific, USA Cat No. N301), reactions were stopped with 0.18 M sulphuric acid and
optical density read at 450 nm on a plate reader (Bio TEK, USA Cat No. EL800). The
experiment was repeated at least three times and a p-value of <0.05 was considered
significant, which was the same for all the experiments unless mentioned otherwise.
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To test the reactivity of serum from a dog with chronic pyoderma, S. aureus SpA and S.
pseudintermedius SpsQ and SpsQ-M were coated on ELISA plates (Corning, USA Cat
No. 3590) at 2 µg/ml in PBS. They were incubated with serum at a dilution of 1:2000.
Bound IgG, IgM, and IgA were detected by HRP- goat anti-dog IgG-heavy and light chain
(Bethyl Laboratories, Inc., USA Cat No. A40-123-1), HRP-goat anti-dog IgM µ chain
(Bethyl Laboratories, Inc., USA Cat No. A40-116-2), HRP-goat anti-dog IgA (Bethyl
Laboratories, Inc., USA Cat No. A40-104P) at a dilution of 1:8000 in PBS-T. Dog whole
IgG molecule (Rockland, USA Cat No. 004-0102-1000) was used for comparison to
measure non-specific IgG binding.
To detect a specific antibody response against SpsQ-M in injected dogs, recombinant S.
pseudintermedius proteins and commercial SpA were coated on ELISA plates as
previously described and incubated with two-fold serially diluted serum from injected dogs
(1/1000-1/32000). Bound IgG was detected using HRP- goat anti-dog IgG-heavy and light
chain (Bethyl Laboratories, Inc., USA Cat No. A40-123-1) with serum from uninjected
dogs used as negative controls. The experiment was run in duplicate and a p-value of
<0.05 was considered significant.
The ability of S. pseudintermedius SpsQ to kill B cells and induce B cell apoptosis
A total of 100 µg of purified recombinant SpsQ or SpsQ-M was mixed with isolated
peripheral blood mononuclear cells (PBMC) in 1 ml of RPMI medium supplemented with
10% fetal bovine serum and incubated for 1.5 h at 37ºC in a 5% CO2 incubator. To detect
early phases of B cell apoptosis, phosphatidylserine was measured on the surface of cells
using pacific blue- conjugated annexin (Thermo Scientific, USA Cat No. A35136). B cells
were identified using phycoerythrin (PE) conjugated mouse anti-canine CD21 (clone:
CA2.1D6) (BIO-RAD, USA Cat No. MCA1781PE) that recognizes canine CD21
(complement receptor type 2) on mature B lymphocytes. Stained B cells were analyzed
using a flow cytometer (Attune acoustic focusing cytometer). B cells were also incubated
with the same recombinant proteins as described above but for 3.5 h in order to detect B
cell death. Cells were stained with Sytox green (Life Technologies, Inc., USA Cat No.
1776406) and PE-conjugated mouse anti-canine CD21. Gates were placed on cells
positive for PE and these B cells were analyzed by flow cytometry.
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To determine the protective effect of canine anti-SpsQ-M on B cells, recombinant S.
pseudintermedius SpsQ was incubated for 30 minutes at 37ºC with serum from SpsQ-M
injected dogs. The experiment was run in duplicate and a p-value of <0.05 was
considered significant.
For flow cytometry analysis the cut-off for apoptosis or cell death was established using
leukocytes incubated without SpsQ. Mean fluorescent intensity was determined from all
B cells.
Statistical Analysis
A one-way ANOVA and Tukey–Kramer method were used to measure the significant
differences between SpsQ, SpsQ-M, and SpA on inducing apoptosis and causing B cell
death. However, two-way ANOVA and Tukey–Kramer methods were performed to test if
there were significant differences in SpA, SpsQ or SpsQ-M binding with canine
antibodies. All analyses were conducted using the GraphPad Prism software (Version 7,
GraphPad Software Inc.).
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CHAPTER 3
CHARACTERIZATION OF A NEW LEUKOCIDIN IDENTIFIED IN S.
PSEUDINTERMEDIUS
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Abstract
Bacterial infections from S. pseudintermedius are the most common cause of skin
infections (pyoderma) affecting dogs. Two component pore-forming leukocidins are a
family of potent toxins secreted by staphylococci and consist of S (slow) and F (fast)
components. They impair the innate immune system, the first line of defense against
these

pathogens.

Seven

different

leukocidins have

been

characterized

in

Staphylococcus aureus, some of which are host and cell specific. Through genome
sequencing and analysis of the S. pseudintermedius secretome using liquid
chromatography mass spectrometry we identified two proteins, named “LukS-I” and
“LukF-I”, encoded on a degenerate prophage contained in the genome of S.
pseudintermedius isolates. Phylogenetic analysis of LukS-I components in comparison
to the rest of the leukocidin family showed that LukS-I was most closely related to S.
intermedius LukS-I and S. aureus LukE and LukP, whereas LukF-I was most similar to S.
intermedius LukF-I and S. aureus gamma hemolysin subunit B. The killing effect of
recombinant S. pseudintermedius LukS-I and LukF-I on canine polymorphonuclear
leukocytes was determined using a flow cytometry cell permeability assay. The cytotoxic
effect occurred only when the two recombinant proteins were combined. Engineered
mutant versions of the two-component pore-forming leukocidins, produced through amino
acids substitutions at selected points, were not cytotoxic. Anti-Luk-I produced in dogs
against attenuated proteins reduced the cytotoxic effect of native S. pseudintermedius
leukotoxin, which highlights the importance of Luk-I as a promising component in a
vaccine against canine S. pseudintermedius infections.
Introduction
S. pseudintermedius is the primary cause of pyoderma (skin infection), the most common
canine dermatologic disease, and is also associated with urinary tract infections, wound
and surgical site infections, external ear otitis, abscess formation, mastitis and
endocarditis (6, 82, 84). Approximately 30- 35% of the S. pseudintermedius isolates
tested in our University of Tennessee College of Veterinary Medicine Bacteriology
Laboratory from patients are methicillin-resistant (MRSP) and high levels of resistance
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occurs in other regions of the United States (84). The vast majority of MRSP are multidrug
resistant and there are increasing numbers of pandrug-resistant isolates (82-84).
Alternative approaches to control staphylococcal infections, such as vaccines, have been
difficult to develop. This is likely rooted in the ability of the bacteria to neutralize and/or
destroy important components of their host defenses. Some staphylococcal toxins impact
the innate immune system, the first line of defense against this pathogen (116-118).
Antibody-mediated

toxin

neutralization

may

contribute

to

a

strategy

for

immunotherapeutic prevention of current and recurrent infections (116, 119).
Leukocidins are a family of potent toxins contributing to the pathogenicity of staphylococci
(120). Leukocidins consist of two classes of proteins designated as S and F subunits (50,
121, 122) based on their chromatographic elution properties where S and F stand for slow
and fast-eluting proteins, respectively (123, 124). The subunits are produced and
secreted separately. The S-component recognizes a receptor on the host cell, conferring
high-affinity binding to the cell surface after which the F component is recruited to form
octameric beta-barrel pores that penetrate the cell lipid bilayer into the plasma membrane
leading to ion influx and efflux, apoptosis and ultimately cell death (50, 121, 122).
A total of seven different bicomponent pore-forming toxins (BCPFTs) have been identified
and characterized in Staphylococcus aureus including HlgAB, LukMF, HlgCB, LukAB/HG,
LukED, Panton-Valentine leukocidins (LukSF-PV/PVL), and LukPQ, some of which are
host and cell specific (116). The encoding genes are located chromosomally
(hlgAB and hlgCB and lukAB/HG), prophage associated (pvl, lukPQ and lukMF) or reside
on a pathogenicity island (LukED) (50, 116-118, 121, 122).
A bi-component toxin (LukS-I + LukF-I) from Staphylococcus intermedius was identified
and characterized previously (125). Descloux et al (126) reported the presence of a
leukocidin encoding gene (LukS-I) in genomes of 15 different S. pseudintermedius strains
(including S. pseudintermedius type strain CCUG49543T) isolated from dogs without
physical characterization of the protein.
In a previous study Karauzum et al. rationally designed mutants of S. aureus LukS-PV
and LukF-PV subunits (54) . They tested mutant versions of LukS-PV with a series of
amino acids substitutions and found that LukS-mut9, with T28F/K97A/S209A, was highly
42

immunogenic and non-cytotoxic when mixed with LukF-PV (54). Rabbit immunoglobulin
raised against LukS-PV reduced the cytotoxic effect of canonical combinations (gamma
hemolysin A and B subunits, gamma hemolysin C and B subunits and LukE and LukD),
non-canonical pairs (gamma hemolysin B subunit and LukE, gamma hemolysin C subunit
and LukD and gamma hemolysin A subunit and LukD) on polymorphonuclear leukocytes
(PMNs) (127). LukS-mut9 vaccines significantly protected in a mouse model of S.
aureus USA300 sepsis and this effect could also be achieved by passive transfer of rabbit
anti-LukS-mut9 antisera (54).
The purpose of the present study was to analyze the secretome of S. pseudintermedius
by mass spectrometry (MS) to determine the abundance of secreted Luk-I, characterize
the cytotoxic effect of recombinant S. pseudintermedius Luk-I on canine PMNs and
develop attenuated, nontoxic LukS-I and LukF-I. Attenuated LukS-I and LukF-I were
tested for their antigenicity and PMN killing. Furthermore, antibody raised against S.
pseudintermedius attenuated Luk-I in clinically healthy dogs was evaluated for its ability
to neutralize wild-type LukS-I and LukF-I. The results from this study suggest that S.
pseudintermedius LukS-I and LukF-I may serve as key components in a vaccine or as
part of an immunotherapeutic approach.
Materials and Methods
Ethics Statement.
Experimental protocols were reviewed and approved by the University of Tennessee
Institutional Animal Care and Use Committee (IACUC) including obtaining blood samples
from dogs (2474-0716) and injecting dogs with recombinant protein for producing
antibodies (2572-1217).
Bacterial strains, plasmids and growth conditions
The S. pseudintermedius strains used in this study, representing the most common
multilocus sequence types (ST) previously reported in the United States (82, 84, 114),
included 06-3228 (ST68), 08-1661 (ST71) and NA45 (ST84) (82, 84, 114). Strains 063228 and 08-1661 were isolated at the University of Tennessee, College of Veterinary

43

Medicine Bacteriology Laboratory. Strain NA45 was a gift of Faye Hartmann of the
University of Wisconsin, School of Veterinary Medicine.
Plasmid construct pMA- attenuated LukS-I and pMA- attenuated LukF-I, each containing
a mutated, synthetic S. pseudintermedius gene (designed as described below) with
BamHI/NotI cloning sites, was obtained commercially (Life Technologies Corp., Carlsbad,
CA).
Bacterial colonies grown on blood agar plates were inoculated into 5ml of sterile trypticase
soy broth (TSB) (BD Biosciences, San Jose, CA Cat No. RS1-011-21) and incubated
overnight at 37°C with shaking at 225 rpm (Excella E24 Incubator Shaker, New Brunswick
Scientific). Fifty microliters of overnight culture were inoculated into 5ml of fresh, sterile
TSB to initiate log-phase bacterial cultures. Bacteria were grown at 37°C with shaking at
225 rpm until an optical density of OD 600 = 0.4-0.6 was reached.
LC-MS/MS Analysis of S. pseudintermedius supernatant
Log-phase bacterial cultures of 06-3228, 08-1661 and NA45 were centrifuged at 10,000
x g for 30 minutes at 4°C (Sorvall RC-5C Plus Super Speed Centrifuge) and the
supernatant was collected and passed through a 0.45μm filter (Whatman, GE Healthcare
Lifesciences, Pittsburgh, PA). The filtrate was concentrated using an Amicon®

Ultra-4

centrifugal filter (EMD Millipore Corp., Billerica, MA) and stored at -20°C until further
analysis. Samples interrogating S. pseudintermedius supernatant/ secretome were
prepared for shotgun LC-MS/MS analysis as previously described (128).
Peptides were separated and analyzed with a 2-step MudPIT LC-MS/MS protocol (salt
cuts of 50 and 500 mM ammonium acetate) over a 4-hr period then measured with a
hybrid LTQ XL-Orbitrap (Thermo Scientific, Waltham, MA) mass spectrometer (MS) at
Oak Ridge National Laboratories, Oak Ridge, Tennessee, USA(129). Peptide
fragmentation spectra were searched against sample-specific proteome databases
(strains 06-3228, 08-1661 and NA45). Matching peptides (FDR < 1%) were assigned to
proteins (130) and resulting secretomes compared. The percent coverage of detected
proteins was calculated by dividing the number of amino acids in all found peptides by
the total number of amino acids in the entire protein sequence.
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Bioinformatics Analysis
Multiple sequence alignment (MSA) of mature LukS-I and LukF-I subunits of S.
pseudintermedius 06-3228 strain with corresponding units in other leukotoxins
(Table 3.1) was performed and a rooted phylogenetic tree (UPGMA (unweighted pair
group method with arithmetic mean)) of Luk-I was generated with Geneious version
11.0.3 (107) with S. pseudintermedius protein A serving as an outgroup.
In order to identify the unique residues in the S-component of S. pseudintermedius Luk-I
that may shape the protein function and specificity, an alignment of amino acid sequences
of the DR4 region in the rim domain (an important region for S-component receptor
binding) of S. aureus LukE, HlgA, LukM and LukP, S. pseudintermedius and S.
intermedius LukS-I was performed.
The

bacterial

localization

prediction

tool,

PSORTb

version

3.0.2

(http://www.psort.org/psortb/) (131) was used to determine the topology and domain
structure of LukS-I and LukF-I.
S. pseudintermedius LukS-I and LukF-I modeling and binding site prediction was
performed using Protein Homology/analogY Recognition Engine V 2.0 (Phyre 2)
(http://www.sbg.bio.ic.ac.uk/phyre2)

(109)

and

the

3DLigandSite

(http://www.sbg.bio.ic.ac.uk/3dligandsite/ ) using S. aureus LukSF-PV, LukED and
LukPQ as a basis to predict the critical amino acids for protein function. PHAST
(http://phast.wishartlab.com/index.html) and PHASTER (132, 133) (http://phaster.ca/)
were used for prophage detection in a total of 22 S. pseudintermedius isolates.
Polymerase chain reaction (PCR) amplification of LukS-I and LukF-I
Bacteria from a single colony of S. pseudintermedius strain 06-3228 obtained from blood
agar plates were grown in TSB at 37°C with 225 rpm shaking. DNA was extracted using
a MO BIO UltraClean® Microbial DNA Isolation Kit (QIAGEN Inc. Cat No.12224-50)
according to the instructions of the manufacturer. Oligonucleotide primers (Integrated
DNA Technology, Coralville, USA) (Table 3.2) were designed using a PrimerQuest Tool
(https://www.idtdna.com/Primerquest/Home/Index) (15) based on the genomic sequence
of S. pseudintermedius strain 06-3228 (20).
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Table 3.1 Leukotoxin subunits used in the rooted phylogenetic tree
Protein name

Species

Accession Number

Amino acid
Length

bi-component leucocidins LukPQ
subunit Q

Staphylococcus aureus

WP_086037611.1

326

bi-component leucocidins LukPQ
subunit P

Staphylococcus aureus

WP_086037612.1

311

bi-component leucocidins LukED
subunit E

Staphylococcus aureus

WP_000473596.1

311

bi-component leucocidins LukED
subunit D

Staphylococcus aureus

WP_099821693 .1

327

bi-component leucocidins LukMF
subunit M

Staphylococcus aureus

WP_000476437.1

308

bi-component leucocidins LukMF
subunit F

Staphylococcus aureus

WP_000694885 .1

322

bi-component leucocidins LukSF- PV
subunit LukS-PV

Staphylococcus aureus

WP_000239544 .1

312

bi-component leucocidins LukSF- PV
subunit LukF-PV

Staphylococcus aureus

WP_024937002 .1

327

bi-component leucocidins Hlg-AB
subunit Hlg-A

Staphylococcus aureus

WP_000594519.1

309

bi-component leucocidins Hlg-AB
subunit Hlg-B

Staphylococcus aureus

WP_000783426 .1

325

S. pseudintermedius LukS-I

Staphylococcus
pseudintermedius

WP_014613568.1

310

S. pseudintermedius LukF-I

Staphylococcus
pseudintermedius

WP_014613567 .1

326

S. intermedius LukS-I

Staphylococcus intermedius

WP_019169129.1

310

S.intermedius LukF-I

Staphylococcus intermedius

WP_086427464.1

325
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Table 3.2 Primers used in this study to amplify recombinant wild-type and
attenuated LukS-I and LukF-I from S. pseudintermedius
NotI, XhoI and BamHI restriction sites are underlined.
LukS-I forward

GCATGAGGATCCGGTAAAAAATAAATTATTAGCCGCAA
CA

LukS-I reverse

GCATGAGCGGCCGCATTATGCCCCTTTACTTTAATTTC
GTG

attenuated LukS-I forward

GCATGAGGATCCAAGGCCACGTGTCTTGTC

attenuated LukS-I reverse

GCATGAGCGGCCGCCCCATGAGGCCAGTCTTG

LukF-I forward

GCATGACTCGAGAAAAGAATGGCTAATCAAATTACACC
TGTATCTG

LukF-I reverse

GCATGAGGATCCTTAGTGATGGTGATGGTGATGTACT
GTATGCTGATCCCAATCAA

attenuated LukF-I forward

GCATGAGGATCCGGATCCAATGAAAATAAGCAAAGTTA
TC

attenuated LukF-I reverse

GCATGAGCGGCCGCGCGGCCGCTGATGGGTTTTTT
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The native LukS-I and LukF-I open reading frames (ORF) (933 and 981 bp, respectively)
without the regions encoding the predicted N-terminal signal peptide were amplified from
S. pseudintermedius 06-3228 genomic DNA and the ORF of mutant LukS-I and LukF-I
were amplified from pMA-attenuated LukS-I and pMA-attenuated LukF-I plasmids (Life
Technologies Corp., Carlsbad, CA), respectively (Table 3.3).
PCR was performed using taq polymerase (rTaq, Takara, Cat No.

R004) and the

following cycling conditions were performed: initial denaturation at 95°C for 90 seconds,
30 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and
extension at 72°C for 1 minute followed by a final extension at 72°C for 5 minutes. All
ORFs were amplified without a histidine tag because pETBlue-2 allowed T7lac promoterbased expression of target genes with C-terminal histidine •Tag® sequences. PCR
products were Sanger sequenced at The University of Tennessee Genomics Core facility.
Table 3.3 Plasmids and competent cells used to clone and express recombinant
wild-type and attenuated S. pseudintermedius LukS-I and LukF-I
Plasmid/

Expressed Gene

Source

Contain attenuated S. pseudintermedius LukS-I

Synthetic gene, Life

Bacteria
pMA- attenuated LukS-I

Technologies Corp.,
Carlsbad, CA
pMA- attenuated LukF-I

Contain attenuated S. pseudintermedius LukF-I

Synthetic gene, Life
Technologies Corp.,
Carlsbad, CA

pETBlue-2

Native and attenuated LukS-I and LukF-I

Novagen, Madison, WI

expression with blue/white screening and Cterminal HSV•Tag® and His•Tag® sequences
DH5-alpha

Cloning and recombinant proteins (wild-type and

Tuner™(DE3) pLacI

attenuated LukS-I and native LukF-I) expression

pKLAC2

An integrative expression vector of S.

New England Biolabs,

pseudintermedius LukF-I in yeast

Ipswich, MA

An expression host of S. pseudintermedius LukF-I

New England Biolabs,

Kluyveromyces lactis

Novagen, Madison, WI

Ipswich, MA
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Cloning, expression and purification of recombinant native and attenuated Luk-I
To clone S. pseudintermedius native and mutant LukS-I and mutant LukF-I, their PCR
products were digested with NotI and BamHI, then ligated into pETBlue-2 (Novagen, Cat
No .70674) and transformed into DH5-alpha E. coli chemically-competent cells (Table
3.3) (New England BioLabs Inc., Cat No .C2987I) by heat shock. The DH5-alpha E. coli
were plated on LB agar plates with 100 µg/mL ampicillin. The plasmid constructs were
transformed into Tuner ™ (DE3) pLacI E. coli chemically-competent cells (Table 3.3)
(Novagen, Cat No .70623) by heat shock and the Tuner ™ (DE3) pLacI E. coli were plated
on LB agar containing 50µg/ml ampicillin and 20µg/ml chloramphenicol.
To express recombinant S. pseudintermedius native and mutant LukS-I and mutant LukFI, a single colony of Tuner ™ (DE3) pLacI E. coli was inoculated into LB broth containing
50µg/ml ampicillin and 20µg/ml chloramphenicol and bacteria grown overnight at 37ºC
with 225 rpm shaking. LB broth containing 50µg/ml ampicillin and 20µg/ml
chloramphenicol was inoculated with a 1:100 dilution of overnight culture and grown at
37ºC with 225 rpm shaking until a 600 nm optical density of between 0.4 and 0.6 was
reached. Protein expression was induced by addition of 1 mM Isopropyl β-D-1thiogalatopyranoside (IPTG) (Teknova, Cat. No. I3431) and bacteria were grown for 4 hr
at 30ºC with shaking at 225 rpm. Bacterial cultures were centrifuged at 12,000 x g for 5
min in 5 ml of protein extraction reagent (BugBuster, Novagen Cat No. 70584) and 20 µl
of 100X protease inhibitor (Cocktail Set III, EDTA-Free Calbiochem, Cat No. 539134) and
incubated for 30 min at 37ºC in a shaking incubator at 225 rpm. Bacteria were pelleted
by centrifugation at 12,000 x g for 45 min at 4°C. Recombinant proteins were purified
using affinity purification (HisPur™ Ni-NTA Spin Purification Kit, Thermo Scientific, Cat
No. 88228).
Recombinant native LukF-I was cloned using an integrative expression vector
(pKLAC2) and expressed in Kluyveromyces lactis (New England Biolabs, Cat No.
E1000S). Recombinant protein was purified from K. lactis supernatant using affinity
purification (HisPur™ Ni-NTA Spin Purification Kit, Thermo Scientific, Cat No. 88228).
Protein concentrations were determined using a bicinchoninic acid (BCA) assay (Thermo
Scientific, Cat No.23227).
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SDS-PAGE and western blot
Protein samples were resolved by SDS-PAGE in 4-12 % polyacrylamide gels (Invitrogen,
Cat No. NP0322BOX) and electrophoretically transferred onto nitrocellulose membranes
(Thermo Scientific, Cat No. 77010). The blots were blocked overnight in 5% (wt/vol)
nonfat dried milk powder in 0.05% polyethylene glycol sorbitan monolaurate (Tween 20)
containing phosphate buffered saline (PBS-T) at 4°C. The blocked membranes were
incubated with a 1:2,000 dilution of horseradish peroxidase (HRP)-conjugated anti-6xhis
tag monoclonal antibody (Thermo Scientific, Cat No. MA1-21315-HRP) in 0.05% PBS-T
for 1 h with 225 rpm shaking at room temperature. After five washes with 0.05% PBS-T
bound antibodies were detected using 1-Step™ chloronaphthol substrate solution
(Thermo Scientific, Cat No. 34012).
Preparation of canine anti- S. pseudintermedius Luk-I
Recombinant attenuated LukS-I and LukF-I produced in E. coli were purified using affinity
chromatography (as above) and endotoxin concentrations were measured using a
ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit (Genscript, Cat. No. L00350).
Recombinant attenuated LukS-I and LukF-I at 20 µg each / 0.5 cc in phosphate buffered
saline (PBS) (pH 7.2) were injected in the lateral thorax by the subcutaneous route, into
three clinically normal dogs. Injections were given once every 7 days for a total of three
injections with a control dog receiving PBS (pH 7.2) only. Blood (6 cc) was collected from
a jugular vein 4 times, on days -7, 8, 15 and 29. The collected blood was left undisturbed
at room temperature for 30 min followed by centrifugation at 2,000 x g for 10 min in a
refrigerated centrifuge.
Enzyme-linked immunosorbent assay
For measurement of recombinant protein antigenicity, attenuated LukS-I and LukF-I were
coated separately onto ELISA plates (Corning, Cat No. 3590) at 2µg/ml in PBS (pH 7.2).
The plates were washed with 0.05% PBS-T and incubated with two-fold serial diluted
serum from dogs (injected with recombinant proteins) for 1 h at 37°C, then bound IgG
was detected using HRP-conjugated goat anti-dog IgG heavy and light chain (Bethyl
Laboratories, Inc. Cat No. A40-123-1). ELISA assays plates were washed three times
with PBS-T between all incubations, bound antibodies were detected using TMB
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substrate (Thermo Scientific, Cat No. N301), reactions were stopped with 0.18 M
sulphuric acid and optical density read at 450 nm on a plate reader (Bio TEK, EL800).
The experiment was repeated a minimum of three times and a p-value of <0.05 was
considered significant for all the experiments unless otherwise stated.
PMN cell permeability assay
Canine blood was collected from healthy dogs using a sterile blood collection system with
EDTA anti-coagulant (BD Vacutainer). Then, 600 µl of dog blood was added to 1 ml of
red blood cell lysing buffer (Hybri-Max™, Sigma-Aldrich, Cat No. R7757-100ML) for 30
min at 37°C in 15 ml sterile plastic tube, centrifuged and re-suspended in 1ml RPMI
medium supplemented with 10% fetal bovine serum. PMNs were incubated with
recombinant proteins (LukS-I and LukF-I, LukS-I alone, LukF-I alone, attenuated LukS-I,
attenuated LukF-I and 1:2 S. pseudintermedius 06-3228 supernatant) in a volume of
500 μl in RPMI medium supplemented with 10% fetal bovine serum in a 5% CO 2 incubator
for 30 min. Supernatant of S. pseudintermedius 06-3228 was harvested at log phase to
test the toxic effect of secreted Luk-I. PMNs were stained with 1 µl of Sytox Green (Life
technologies, Inc. Cat No. 1776406) for 30 min, washed with PBS (pH 7.2) twice and
analyzed using a flow cytometer (Attune acoustic focusing cytometer). In order to
measure the protective effect of anti-Luk-I on canine PMNs, recombinant LukS-I and
LukF-I were incubated with canine anti- Luk-I at a dilution of 1:100 for 30 min at 37°C,
then tested with the cell permeability assay as previously described.
Biotin labeling of S. pseudintermedius wild type and attenuated Luk-I and single
components
Purified recombinant S. pseudintermedius wild type and attenuated LukS-I and LukF-I at
500 µg/ml in PBS (pH 7.2) were incubated with 50μl of 10mM EZ-Link Sulfo-NHS-LCBiotin reagent (equal to 20 fold molar excess of biotin) (Thermo Scientific, Cat No. 21327)
for 30 min at room temperature. Excess biotin was removed using an Amicon Ultra-0.5
Centrifugal Filter Unit with a 30 kDa molecular weight cut-off (Milipore sigma, Cat No.
UFC5030). The biotin-labeled proteins were stored at -20°C until further use.
To test the binding of wild type and attenuated LukS-I and LukF-I to canine PMNs, biotin
labelled recombinant proteins were incubated with PMNs from a clinical healthy dog for
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30 minutes at room temperature, the cells were washed, then PMNs were incubated with
1:500 dilution of avidin-FITC conjugate (Sigma-Aldrich, A2050) at room temperature for
30 minutes in the dark. Unbound conjugate was removed by washing and the amount of
binding was determined using a flow cytometer (Attune acoustic focusing cytometer).
Statistical Analysis
Data was analyzed using ANOVA tests and followed by post hoc multiple comparisons
with Tukey’s adjust. Diagnostic analysis was performed on residuals for checking
normality and equal variance assumptions. Rank data transformation was applied when
assumptions were violated. Statistical significance was identified at the level of 0.05.
Analyses were conducted in JMP pro 14 for Windows (SAS institute Inc., Cary, NC).
Results
LC MS/MS data analysis of S. pseudintermedius culture supernatant
Secreted proteins, were isolated and digested to peptides with trypsin and analyzed by
LC-MS/MS. The high mass accuracy of intact peptides and their fragmentation profiles
were searched against genome-derived amino acid sequences for each protein in the
sequenced genome of each strain. Identified peptides were then mapped back to their
respective proteins and proteins quantified by both sequence coverage as well as areaunder-the-curve abundance. Using this semi-quantitative data, along with categorizing
each protein by their predetermined cellular location (pSORT), we were able to identify
both LukS-I and LukF-I proteins in supernatant at relatively high levels. They occurred in
rank 5 (LukF-I) and rank 7 (LukS-I) out of 92 total extracellular proteins identified (PSORT:
extracellular, membrane/cell wall-associated, location unknown), putting both in the top
10% of the extracellular dataset. Thus, MS identification confirmed the extracellular
existence of these proteins in all virulent strains and that they are indeed expressed at
relatively high-levels, thus serving as candidates for further analysis (presented here and
on-going).
The percent coverage of LukS-I and LukF-I were calculated by dividing the number of
amino acids in all found peptides by the total number of amino acids in the mature protein
sequence (Table 3.4).
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Table 3.4 LC MS/MS analysis of S. pseudintermedius culture supernatant
Coverage
06-3228 strain
LukS-I

10.0

LukF-I

39.3

08-1661 strain
LukS-I

56.2

LukF-I

46.0

NA45 strain
LukS-I

59.4

LukF-I

62.3

LukS-I and LukF-I were secreted by S. pseudintermedius 06-3228, 08-1661 and NA45.
Secretome proteins were compared among the three isolates using their respective
genomes as reference databases, the percent coverage was calculated by dividing the
number of amino acids in all found peptides by the total number of amino acids in the
entire protein sequence.
Characterization of S. pseudintermedius Luk-I
Multiple sequence alignment (MSA) analysis showed that Luk-I is conserved among S.
pseudintermedius strains including 06-3221, 08-1661 and NA45 with amino acid identities
over 99.4 % between strains.
A 14.9 kb incomplete prophage (similar to Φ Staphy_96_NC_007057) was identified in
the genome of S. pseudintermedius 06-3228. A BLAST search of Φ
Staphy_96_NC_007057 using complete genome sequences of S. pseudintermedius
strains available in the GenBank database and others sequenced in our lab but not yet
published, revealed that approximately 7 Kb of the phage are present in all of the S.
pseudintermedius isolates examined ( a total of 22 isolates). They also contain the coding
DNA sequences (CDS) of ascorbate-specific PTS system EII A, B and C components,
53

probable L-ascorbate-6-phosphate lactonase UlaG (L-ascorbate utilization protein G),
phosphoglycerate mutase family 2 and hypothetical protein.
Phylogenetic analysis of Luk-I in comparison to the entire leukocidin family showed that
S. pseudintermedius LukS-I is closely related to S. intermedius LukS-I, S. aureus LukE
and LukP. However, S. pseudintermedius LukF-I is closely related to S. intermedius LukFI and S. aureus gamma hemolysin subunit B (Figure 3.1).
Multiple sequence alignment (MSA) analysis showed that Luk-I in S. pseudintermedius is
a unique leukotoxin and that each functional component shares considerable similarity
with other staphylococcal leukotoxin fractions (Table 3.5).

Figure 3.1 Phylogenetic tree based on amino acid sequences of mature leucocidins
produced by S. aureus, S. intermedius and S. pseudintermedius.
S. pseudintermedius LukS-I is closely related to S. intermedius LukS-I, S. aureus LukE
and LukP. S. pseudintermedius LukF-I is closely related to S. intermedius LukF-I and S.
aureus gamma hemolysin subunit B. S. pseudintermedius protein A was used as an
outgroup.
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Table 3.5 MSA of LukS-I and LukF-I subunits of S. pseudintermedius 06-3228 strain
with corresponding units in other leukotoxins
LukP

S.pseudintermedius

hlgA

LukE

LukM

LukS-

S. intermedius

PV

LukS-I

75.64%

73.08%

73.72%

68.49%

64.76%

85.48%

LukF-

LukQ

LukF

LukD

hlgB

S. intermedius

LukS-I

LukF-I

PV

S.pseudintermedius

73.60%

74.54%

73.46%

76.07%

72.62%

79.75%

LukF-I

The protein sequence contains an N-terminal signal peptide sequence from positions 1
through 29 for LukS-I and 1 through 26 for LukF-I detected by SignalP 4.1 server (134).
The LukF-I model developed with the Phyre2 web portal, shows that LukF-I consists of βstrands organized as four antiparallel β-sheets and three very short α-helices (Figure
3.2). LukF-I, similar to the fold organization of other bicomponent pore-forming toxins, is
arranged in three typical domains: β-sandwich (cap) (1-60, 79-107, 147-169, 220-246 and
569-300), stem (108-146) and rim (61-78, 170-219 and 247-268)) (Figure 3.3, a). The
rim domain has critical residues for membrane binding, the β-sandwich (cap) domain
plays a role in side by side residues interaction and oligomerization with S component,
and the pre-stem domain is important for pore formation but not membrane-binding.
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Figure 3.2 Ribbon representation of Wild-type and attenuated S. pseudintermedius
LukS-I and LukF-I proteins.
Colour-ramped from the N terminus (blue) to the C terminus (red). The output structure
was generated with Pymol.
In S. pseudintermedius LukF-I, we identified tyrosine (Y) 71, tryptophan (W) 176, arginine
(R) 179, W256, phenylalanine (F) 259 and histidine (H) 260 as critical residues located in
the rim domain, important for phospholipid binding on the membranes of canine PMNs
while serine (S) 33 and asparagine (N) 39 located in the β-sandwich (cap) domain are
essential for interaction with side residues of LukS-I which stimulate oligomerization.
These residues are conserved among S. intermedius LukF-I and S. aureus LukD (Figure
3.3, b).
MSA of amino acid sequences of the divergent region 4 (DR4) in the rim domain (an
important region for S-component receptor binding) of S. aureus LukE, HlgA, LukM and
LukP, S. pseudintermedius LukS-I and S. intermedius LukS-I revealed that the DR4
regions of S. aureus LukP and LukS-I of S. pseudintermedius and S.intermedius are
almost identical. By comparison, LukM, HlgA and LukE are considerably different (Figure
3.3, c).
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Figure 3.3 Unique residues in S and F-components of S. pseudintermedius Luk-I
may shape the protein function and specificity
(a) domain structure of S. pseudintermedius LukF-I consist of β-sandwich (cap) domain
highlighted in orange color (1-60, 79-107, 147-169, 220-246 and 569-300), stem
highlighted in yellow (108-146) and rim highlighted in blue (61-78, 170-219 and 247-268).

Figure 3.3 (b), Multiple sequence alignment (MSA) of S. intermedius and S.
pseudintermedius LukF-I and S. aureus LukD. Geneious version 11.0.3 was used to
generate the alignment. Residues unique to S. pseudintermedius LukF-I are highlighted
yellow, residues identified as important for phospholipid interaction are shown in red and
underlined text and residues important for oligomerization is highlighted in blue.
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Figure 3.3 (c) MSA of amino acid sequences of the DR4 region (highlighted in yellow) in
the rim domain (an important region for S-component receptor binding) of S. aureus LukE,
HlgA, LukM and LukP, S. pseudintermedius LukS-I and S. intermedius LukS-I. The DR4
regions of S. aureus LukP and LukS-I of S. pseudintermedius and S.intermedius are
almost identical, whilst that of LukM, HlgA and LukE are considerably different.

Design of LukS-I and LukF-I with amino acid substitutions
We designed attenuated LukS-I and LukF-I with mutations away from the rim region to
disrupt the ability of LukS-I and LukF-I to interact side by side and form oligomers, a
function critical for cytolysis.
S. pseudintermedius LukS-I and S. aureus LukS-PV share the critical residues T28, K99
and S211 for interaction and oligomerization with the corresponding F-component (54).
Guided by the LuKS-I protein model developed by Phyre2, and MSA of amino acid
sequences of S. pseudintermedius LukS-I and S. aureus LukS-PV (Figure 3.3, d), an
attenuated S. pseudintermedius LuS-I was designed with the following substitutions:
T28F, K99A and S211A.
Moreover, we identified serine (S) 59 and asparagine (N) 65 in the mature LukF-I protein
as residues essential for side-by-side interactions with LukS-I to form oligomers. To test
this, we designed attenuated LukF-I with the following substitutions: S59D and N65A.
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Figure 3.3 (d) MSA of amino acid sequences of S. pseudintermedius LukS-I and S.
aureus LukS-PV showing the critical residues T28, K99 and S211 (highlighted in yellow)
that interact with the corresponding F-component.
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Cloning, expression and purification of recombinant S. pseudintermedius LukS-I
and LukF-I
Recombinant polyhistidine tagged wild type and mutant LukS-I and LukF-I were
generated in E. coli and LukF-I was secreted in the culture supernatant of K. lactis using
an integrative expression vector (pKLAC2). Recombinant proteins were purified using
HisPur Ni-NTA resin under native conditions and eluted using an imidazole gradient. The
molecular weights of LukS-I, attenuated LukS-I, LukF-I and attenuated LukF-I,
determined in western blots, were of the expected sizes (39.43, 39.12, 37.27 and 37.59
kDa, respectively) (Figure 3.4). The endotoxin levels of purified recombinant, attenuated
LukS-I and LukF-I were below 0.5 endotoxin units /mg protein.

Figure 3.4 Western blot of recombinant S. pseudintermedius wild-type and
attenuated LukS-I and LukF-I with HRP-conjugated anti-6xhis tag monoclonal
antibody. The Molecular weights of LukS-I, LukF-I, attenuated LukS-I and attenuated
LukF-I determined in western blots using SeeBlue® Pre-Stained Protein Standard (x
1,000) were of the expected sizes 39.43, 39.12, 37.27 and 37.59 kDa, respectively.
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Attenuated Luk-I induces specific antibody responses
Specific antibodies against S. pseudintermedius wild type and attenuated LukS-I and
LukF-I were measured by ELISA (described below) in sera collected on days -7, 8, 15
and 29, relative to antigen injections. Antibodies were detected after the second injection
of attenuated Luk-I (on day 15) and were highest on day 29 (P < 0.0001) compared to
pre-injection control sera (Figure 3.5).
Luk-I kills canine PMNs
Canine PMNs were highly susceptible to Luk-I with lysis induced within 30 minutes at a
concentration of 200 ng of each leukototxin component and a 1:2 S. pseudintermedius
06-3228 supernatant dilution (Figure 3.6, a). The mean fluorescent intensity (MFI) of
PMNs treated with wild-type LukS-I (P = 0.0330***) and LukF-I (P = 0.0468**) was
significantly lower than that with Luk-I treatment. PMNs killing represented in MFI was
significantly lower in attenuated LukS-I (P = 0.0276**), attenuated LukF-I (P = 0.0268**)
and attenuated Luk-I treatments (P = 0.0044***) compared to that with 1:2 S.
pseudintermedius 06-3228 supernatant dilution (Figure 3.6, b).
Amino acid substitutions in S. pseudintermedius LukS-I and LukF-I did not
abolish leukotoxin binding to canine PMNs
To test the effect of critical amino acid substitutions on attenuated LukS-I and LukF-I
binding to canine PMNs, biotin labelled recombinant wild type and attenuated LukS-I and
LukF-I were incubated with canine PMNs and their binding detected using FITC
conjugated avidin. No significant difference in MFI of attenuated or wild type recombinant
LukS-I and LukF-I was found (P >0.05) (Figure 3.7).
Dog Anti-Luk-I reduced the cytotoxic effect of canine leukotoxin on PMNs
Dog anti-Luk-I at a dilution of 1:100 preincubated with Luk-I showed a significant reduction
in mean fluorescent intensity (MFI) compared with Luk-I treatment alone (P = 0.0036**)
and with that of 06-3228 supernatant treatment alone (P = 0.0002***) (Figure 3.8).

61

L u k F -I

L u k S -I
3 .0

3 .0

****

2 .5

post 1

st

post 2

in je c t io n

nd

in je c t io n

2 .0
p o s t im m u n e s e r u m

****

1 .5
****

1 .0

****

0 .5
0 .0

p r e -im m u n e d o g s e r u m

A b so r b a n c e (O D 4 5 0 )

* * **

2 .5

post 1
post 2

2 .0

st
nd

in je c tio n
in je c tio n

p o s t im m u n e s e r u m

1 .5

* * **

1 .0

* * **

* * **

0 .5

0
1/

1/

16

32

00

00

0

00
1/

80

00
40
1/

20

00
1/

1

10

2
/3

6
/1
1

d o g s e r u m d ilu t io n

00

0
0
0

0
0

0
1

/8

0
/4
1

0

0
0

0
0

0
0
/2
1

1

/1

0

0

0

0

0 .0

1/

A b so r b a n c e (O D 4 5 0 )

p r e - im m u n e d o g s e r u m

d o g s e r u m d ilu tio n

Figure 3.5 Canine antibody against attenuated LukS-I and LukF-I react with
recombinant wild-type LukS-I and LukF-I.
Antibodies against S. pseudintermedius wild-type LukS-I and LukF-I were detected using
an indirect ELISA. Recombinant S. pseudintermedius LukS-I and LukF-I proteins were
coated on ELISA plates, then incubated with two-fold serially diluted serum from dog
vaccinated with the same proteins. High reactivity with LukS-I and LukF-I was seen from
sera collected two weeks after 3rd injections of attenuated LukS-I (P =0.0001****) and
LukF-I (P =0.0001****) compared to pre-injection sera. The values represent averages
from three independent experiments.
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Figure 3.6 Cytotoxic effect of S. pseudintermedius recombinant Luk-I on canine
PMNs. PMN permeability assay using Sytox Green to detect the cytotoxic effect of wildtype Luk-I on canine PMNs. (a) Luk-I significantly induced PMN killing after 30 min
compared to that with wild-type LukS-I (P = 0.0330***) and LukF-I (P = 0.0468**).
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Figure 3.6 (b) A1:2 S. pseudintermedius 06-3228 supernatant dilution significantly
induced PMN killing after 30 min compared to that with and attenuated LukS-I (P =
0.0276**), attenuated LukF-I (P = 0.0268**) and attenuated Luk-I treatments (P =
0.0044***)
The mean fluorescent intensity (MFI) of all treatment were calculated based on average
values from three independent experiments. (*P < 0.05 was considered significant). ns –
Not significant.
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Figure 3.7 S. pseudintermedius wild-type and attenuated Luk-I binding to canine
PMNs
Biotin labelled recombinant wild type and attenuated LukS-I and LukF-I were incubated
with canine PMNs and their binding was detected using FITC conjugated avidin. MFI of
the blank, wild-type and attenuated proteins were calculated based on average values
from three independent experiments. All of the recombinant proteins bind to canine PMNs
with no significant difference (ns).
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Figure 3.8 Dog antibody raised against attenuated LukS-I and LukF-I protects
canine PMNs from the cytotoxic effect of Luk-I
The PMN permeability assay was performed. Luk-I preincubated with dog anti-Luk-I
resulted in a significant reduction in the mean fluorescent intensity (MFI) compared with
that

of Luk-I treatment

alone

(P

=

0.0036**)

and

with

that

of

06-3228

supernatant treatment alone (P = 0.0002***).
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Discussion
In this study we identified a bicomponent leukotoxin, Luk-I, composed of LukS-I and LukFI proteins secreted by S. pseudintermedius that kills canine PMNs by pore formation and
cell lysis. Luk-I, a member of the leukocidin family, is highly conserved among S.
pseudintermedius isolates. It is associated with an incomplete prophage that occurs in
degenerate form across all S. pseudintermedius isolates for which genomic sequence is
available.
In accordance with its host distribution in a canine opportunistic pathogen, Luk-I is
cytotoxic against dog PMNs. This highlights the immune-evasive attribute of S.
pseudintermedius Luk-I in the dog, in line with the assumed function of other phageencoded leukocidins that similarly have a host-specific function and distribution. For
example, LukMF is highly toxic to ruminant neutrophils and LukPQ preferentially kills
horse neutrophils (116, 117, 135).
Based on the crystal structure of the β-sandwich (cap) domain of S. aureus γ-hemolysin
LukF component and a S. pseudintermedius LukS-I and LukF-I model, we designed
attenuated LukS-I and LukF-I with mutations away from the rim region. The attenuated
LukS-I and LukF-I bind to canine leukocytes without causing any significant killing,
indicating that mutations disrupt the ability of attenuated LukS-I and LukF-I to oligomerize,
an essential function required for cytolysis. This observation is in agreement with the
findings of Karauzum et al (54) with LukS-Mut9. The low concentration of endotoxin in the
recombinant proteins and the low toxicity exhibited by the attenuated protein produced in
E. coli suggests that endotoxin did not play a role in neutrophil killing.
Expression of LukF-I in E. coli was not successful and for unknown reasons this protein
appeared to be lethal to these bacteria; therefore, a yeast protein expression system (K.
lactis) was used for this protein. K. lactis is considered the best alternative to bacterial
expression systems. It efficiently produces recombinant proteins in culture supernatant
that are also secreted by their native host (136-138). K. lactis protein expression is driven
by a variant of the strong PLAC4 promoter (PLAC2) (139) that lacks background
expression in E.coli (136).
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The high titer of Luk-I-specific, neutralizing antibodies produced in a clinically healthy dog
injected with attenuated LukS-I and LukF-I is similar to the antibody production that
Karauzum et al (54) and Adhikari et al (127) observed with LukS-PV mutant (PVL- S
subunit) named “LukS-mut9” injected in mice.
With widespread antimicrobial resistance, it is critical to find alternative approaches, such
as vaccines, to control staphylococcal infections. Previous studies (140-142) concluded
that a multivalent vaccine would likely work best in preventing infections caused by S.
aureus. Taking the same factors into account, a potent and effective vaccine against S.
pseudintermedius would involve identifying antigenic targets conserved among a wide
variety of strains and sequence types. Understanding the nature of extracellular proteins
and their role in virulence and pathogenesis is critical for vaccine development against S.
pseudintermedius infection.
Using mass spectrometry and genomic information, it was possible to identify a unique
leucocidin present in S. pseudintermedius isolates 06-3221, 08-1661 and NA45,
representing the three clonal complexes that predominate in the United States (82).
Conclusions
In conclusion, we describe a unique pore-forming toxin from S. pseudintermedius. Mutant
versions of the proteins had a reduced cytotoxic effect on dog PMNs, and anti-Luk-I
produced in dogs against attenuated proteins reduced the cytotoxic effect of wild type
canine leukotoxin. Therefore, these mutants may serve as important components of a
multivalent vaccine for prophylaxis or control of S. pseudintermedius infections. Such a
vaccine may neutralize extracellular toxins responsible for host tissue destruction and
immunosuppression and may help the host immune system control infections
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CHAPTER 4
COMPLETE GENOME SEQUENCE OF S. PSEUDINTERMEDIUS TYPE
STRAIN LMG 22219
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A version of this chapter was originally published by Mohamed A. Abouelkhair, Matthew
C. Riley, David A. Bemis, Stephen A. Kania:

Abouelkhair MA, Riley MC, Bemis DA, Kania SA. Complete Genome Sequence
of Staphylococcus pseudintermedius Type Strain LMG 22219. Genome Announc.
2017;5(7).

No revisions were made to the original published manuscript beyond general formatting
to allow consistency through the dissertation. My contributions to this paper include: (i)
selection of isolates (ii) experimental design and set up (iii) experimental testing (iv)
data analysis (v) gathering and review of literature (vi) formulation of discussion topics
(vi) writing.
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We report the first complete genome sequence of LMG 22219 (=ON 86
(T)

=CCUG 49543 (T)), the S. pseudintermedius type strain isolated from

feline

lung

tissue.

This

sequence

information

will

facilitate

phylogenetic comparisons of staphylococcal species and other
bacteria at the genome level.
Here we present the first complete genome sequence of LMG 22219 (=ON 86 (T) =CCUG
49543 (T)), the S. pseudintermedius type strain isolated from lung tissue of a cat (18). S.
pseudintermedius is a Gram-positive opportunistic bacterial pathogen (143) commonly
associated with canine pyoderma and occasionally isolated from human infections (144147). It was first defined as a unique species by Devriese et al (18). This species is
classified as a member of the Staphylococcus intermedius group which also includes S.
intermedius and S. delphini, as defined by Takahashi et al. (148). S.pseudintermedius is
characterized by non-pigmented colonies surrounded by double zone hemolysis on
Columbia sheep blood agar. It is catalase-positive and coagulates rabbit plasma but is
clumping-factor-negative in slide coagulase testing. S.pseudintermedius is positive for
DNase, β-glucosidase, arginine dihydrolase, urease, nitrate reduction, pyrrolidonyl
arylamidase and ONPG (β-galactosidase). It does not produce β-glucuronidase and is
susceptible to 8 μg acriflavine ml −1 and to novobiocin. It is also resistant to deferoxamine
(18).
Whereas assays exist to differentiate S. pseudintermedius from other Staphylococcus
intermedius group species, it may be misidentified in veterinary and human medicine
(147, 149). Clinical treatment of infections relies upon accurate pathogen identification
(150) and the availability of the complete genome for this organism may allow for genetic
validation of phenotypic testing as well as identification of new genetic targets for
interspecies comparisons. Only genome sequences of S. intermedius and S. delphini
(151) type strains are currently available and consequently the elucidation of the genome
sequence of the S. pseudintermedius Type Strain LMG 22219 will facilitate comparisons
of different species and strains based on genetic analysis.
DNA was extracted and a library prepared using the Nextera XT library preparation kit in
accordance with the instructions of the manufacturer. Sequencing was performed using
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Illumina MiSeq V2 (Illumina Inc., USA) and De novo assembly was performed using
Geneious v.9.1.6 (107). Automated annotation of assembled contigs was performed
using

the

NCBI

Prokaryote

Genome

Annotation

Pipeline

(http://www.ncbi.nlm.nih.gov/genome/annotation_prok).
A total of 1,432,416 MiSeq paired-end reads were used to generate 50 contigs with > 100
x average depth of coverage. The LMG 22219 genome is comprised of
2,523,112 base pairs with 37.6% GC content, 2,242 predicted coding sequences and 81
RNAs.
Accession numbers. This whole-genome has been deposited at DDBJ/ENA/GenBank
under the accession no. MLGE00000000. The version described in this paper is version
MLGE00000000.1.
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CHAPTER 5
IDENTIFICATION, CLONING AND CHARACTERIZATION OF SPEX
EXOTOXIN PRODUCED BY S. PSEUDINTERMEDIUS
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Abstract
Staphylococci have evolved numerous strategies to evade the immune system of their
hosts. Some staphylococcal toxins target essential components of host innate immunity,
one of the two main branches of the immune system. Analysis of the S. pseudintermedius
secretome using liquid chromatography mass spectrometry guided by genomic data, was
used to identify an S. pseudintermedius exotoxin provisionally named SpEX. This
exoprotein has low overall amino acid identity with the Staphylococcus aureus group of
proteins named staphylococcal superantigen like proteins (SSLs) and staphylococcal
enterotoxin- like toxin X (SEIX), but predictive modeling showed that it shares similar folds
and domain architecture to these important virulence factors. In this study, we found
SpEX binds to complement component C5, prevents complement mediated lysis of
sensitized bovine red blood cells, kills polymorphonuclear leukocytes and monocytes and
inhibits neutrophil migration at sub-lethal concentrations. A mutant version of SpEX,
produced through amino acid substitution at selected positions, had diminished
cytotoxicity. Anti-SpEX produced in dogs reduced the inhibitory effect of native SpEX on
canine neutrophil migration and protected immune cells from the toxic effects of the native
recombinant protein. These results suggest that SpEX likely plays an important role in S.
pseudintermedius virulence and that attenuated SpEX may be an important candidate for
inclusion in a vaccine against S. pseudintermedius infections.
Introduction
S. pseudintermedius is the main cause of canine dermatological disease and has been
isolated from wound and surgical site infections, endocarditis and mastitis in dogs (6, 18).
Human infections with this organism have been reported sporadically, most of which have
been related to exposure to dogs (80). As many as 30-40% of the S. pseudintermedius
isolates tested in clinical laboratories in different geographical areas are methicillinresistant (MRSP) (7). Most MRSP are multidrug-resistant leaving few treatment options.
The transfer of resistance genes to human organisms as well as direct transfer of
multidrug-resistant S. pseudintermedius between animals and to humans are theoretical
concerns (82-85). Development of alternative approaches to control staphylococcal
infections, such as vaccines, is challenging. S. pseudintermedius may evade the immune
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response of their hosts by producing a number of cell surface and secreted proteins that
target essential components of the host defense, promoting the survival and transmission
of this pathogen. S. pseudintermedius, like Staphylococcus aureus, produces
hemolysins, exfoliative toxins, leukotoxins, thermonuclease, protein A, coagulase and
adenosine synthase (13, 15-17, 21). However, many of these virulence factors are not
well characterized in S. pseudintermedius and others likely remain to be identified.
Innate immunity involving neutrophils is an important first step in the defense against
staphylococci and migration from blood provides the majority of these effectors. This
process is triggered by inflammatory signal molecules such as C5a, neutrophils bind to
upregulated endothelial selectins,

extravasate and migrate toward the site of

inflammation (63). However, neutrophils are susceptible to staphylococcal defenses
including molecules that inhibit neutrophil function and leukotoxins that kill by forming
pores in their cell membranes (152) .
The roles of structurally related S. aureus secreted virulence factors staphylococcal
superantigen-like proteins (SSLs) and staphylococcal enterotoxin-like toxin (SEIX) in
inhibiting the innate immune response of their hosts are well characterized. SSLs are
distinguished from SEIX by their lack of cytotoxic activity. SSLs are two- domain proteins
with an average size of 25 kDa (64, 65). The first domain, located at the N-terminus,
displays an oligosaccharide/ oligonucleotide binding (OB) fold forming a β- barrel. The
second domain possesses a β-grasp motif consisting of a twisted β-sheet of four to five
antiparallel strands, located at the C-terminus. The two domains are separated by a
structurally conserved α-helix. SSLs target innate immunity components but do not bind
to T cell receptors or the major histocompatibility complex (67, 153).
In previous studies, S. aureus SSL4 (67), SSL5 (65) and SSL11 (65), were found to
interfere with neutrophil migration through their sialated glycan-binding site in the Cterminal β-grasp domain. Chung et al., (68) showed that SSL11 with a single site
mutation, T168P, had defective binding compared to native SSL11 and lost its inhibitory
effect on neutrophil attachment to P-selectin. The OB fold domain of SSL7 binds to the
IgA Fc region while the β-grasp motif adheres tightly to complement component C5
resulting in inhibition of complement mediated hemolytic activity (65). SSL3 binds to and
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inhibits toll-like receptor (TLR) 2 using a well characterized recognition site not found in
other SSLs (118). Tuffs et al., (66) showed that SEIX secreted by S. aureus shares its
domain structure with SSLs. As with SSLs, SEIX binds to neutrophils, however, it also
exhibits a superantigenic effect via its OB fold on T cells (66, 67).
In this study, we used a proteomic approach to identify an exoprotein produced by S.
pseudintermedius, SpEX.

It is most closely related to and shares some biological

properties and domain structures with SSLs and SEIX, however, it has less than 50%
amino acid similarity with SSL proteins and has key distinguishing properties. It is often
annotated in S. pseudintermedius as exotoxin 15, a synonym for SSL11, formerly referred
to as staphylococcal exotoxin-like proteins (SET) (154). SpEX was studied to determine
if it had immunosuppressive effects on the innate immune system of their hosts. The
specific objectives of this study were to characterize the immunobiological properties of
S. pseudintermedius SpEX and attenuated (reduced toxicity) SpEX (SpEX-M) by
measuring their inhibitory effects on complement activity, neutrophil migration and
cytotoxic effects on PMNs and monocytes. Antibody against SpEX-M was developed in
clinically healthy dogs and the neutralizing activity of those antibodies was evaluated.
Results
Identification of putative immune modulator from S. pseudintermedius
Liquid chromatography–mass spectrometry (LC-MS/MS) was used to screen culture
supernatants of three clinical strains of S. pseudintermedius (06-3228, 08-1661 and
NA45), representing the major S. pseudintermedius genotypes occurring in the United
States as determined by multilocus sequence typing (8). We identified over 500 secreted
or cell wall associated proteins and others with unknown cellular locations (manuscript
under review). The secretome proteins were compared among 06-3228, 08-1661 and
NA45 strains using their respective genomes as references. SpEX, a 234-aa protein, was
detected in the supernatants of the three isolates. The mean predicted molecular weight
was 26.093 kDa with a mean isoelectric point of 6.30.
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Bioinformatics analysis of S. pseudintermedius SpEX
A BLAST search of SpEX in the GenBank database revealed that it is conserved
among S. pseudintermedius strains including 06–3221, 08–1661 and NA45 with amino
acid identities over 88% between strains. SpEX shares sequence similarity with other
pathogenic bacterial species within the Staphylococcus intermedius group. It shares
amino acid identity of 71.8% with Staphylococcus intermedius, 73.5% with
Staphylococcus delphini and 72.2% with Staphylococcus cornubiensis. No similar
proteins were identified in S. aureus. SpEX has approximately 47% amino acid sequence
identity with S. aureus SSL11 and less than 30% amino acid identity with other SSL
members and SEIX.
Analysis of SpEX secondary and tertiary domain structures using Geneious 11.0.3
software (107) supported by a SpEX model developed with the Phyre2 web portal showed
that S. pseudintermedius SpEX share fold and domain architecture with S. aureus SSLs
and SEIX (Figure 5.1, a and b). The SpEX protein sequence contains a signal peptide
sequence from positions 1 through 35 detected using SignalP 4.1 (134). SpEX has an Nterminal OB domain in residues 43-126 that folds into a five-stranded beta-barrel structure
consisting of β-strands (β1- β5) and a C-terminal β grasp motif in residues 150-234
(Figure 5.1, a). This comprises a β sheet formed from β7, β6, β12, β9 and β10 with a
characteristic central helix orientated diagonally in the center of the field from the top left
to the bottom right leaving the N-terminal domain on the left and C-terminal domain on
the right (Figure 5.1, b).
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Figure

5.1

S.

pseudintermedius

SpEX

structural

characteristics

(a) SpEX of S. pseudintermedius harbors an N-terminal signal peptide (green arrow) from
position 1-35, OB domain (orange arrow) in residues 43-126 and C-terminal β grasp
domain in residues 150-234 (orange arrow).

Figure 5.1(b) The 3D model of S. pseudintermedius SpEX and S. aureus SSL11 shows
the N and C terminal domains fold into a five-stranded beta-barrel structure consisting of
β1- β5 and β7, β6, β12, β9 and β10. A central helix is orientated diagonally in the center
of the field from the top left to the bottom right leaving the N-terminal domain on the left
and C-terminal domain on the right. A conserved sialated glycan binding domain forming
V-shape depression is highlighted in purple in SpEX and SSL11 3D models.
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S. aureus SSL4 (accession number: WP_000705627.1), SSL5 (accession number:
WP_000784244.1), SSL11 (accession number: WP_000769163.1) and SEIX (accession
number: AEI60186.1) proteins have been shown to bind sialated glycan through a
conserved sialated glycan binding domain located at the C-terminal β grasp domain (67,
68, 155). It has the capacity to influence the innate immunity defenses through targeting
sialated glycoproteins at the surface of immune cells. Amino acid multiple sequence
alignment of SpEX with previously characterized S. aureus SSL4, SSL5, SSL11 and SEIX
proteins showed that S. pseudintermedius SpEX possesses the conserved sialated
glycan binding site of the SSLs located at the C-terminal region and forming the V-shape
depression in the 3D model of SpEX (Figure 5.2).
In S. pseudintermedius SpEX, we predict aspartic acid (D) 102 and threonine (T) 125 in
the OB- fold domain are critical residues for the cytotoxic effect of the protein on immune
cells. T 206, serine (S) 208, lysine (K) 211, leucine (L) 213, glutamine (Q) 214, arginine
(R) 217 and isoleucine (I) 227 lining the sides of the glycan binding domain were predicted

Figure 5.2 Multiple sequence alignment of SpEX glycan binding domain with S.
aureus SSL and SEIX. Proteins with accession numbers are SSL4 (WP_000705627.1),
SSL5 (WP_000784244.1), SSL11 (WP_000769163.1) and SEIX (AEI60186.1).
Threonine (T) 206, serine (S) 208, lysine (K) 211, leucine (L) 213 and arginine (R) 217
are identical among all analyzed proteins (five proteins). The numbers refer to the position
of the amino acids in full length SpEX protein.
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as essential for binding to monocytes, neutrophils and complement. These residues are
highly conserved among SSLs and SEIX proteins.
Design of SpEX with amino acid substitutions
An attenuated S. pseudintermedius SpEX (SpEX-M) was designed with (D102A and
T125P) in the OB-fold domain and (T206P and R217A) in the sialated glycan binding
domain (Figure 5.3).
To ensure that protein stability and folding were not altered, only amino acids highly
conserved within functional domains of S. pseudintermedius SpEX and S. aureus SSL4,
SSL5, SSL11 and SEIX were selected. Furthermore, the designed SpEX was first
modelled in the structure to confirm that its conformation was maintained (Figure 5.3).

Figure 5.3 Residues substituted to produce attenuated S. pseudintermedius SpEXM
Pairwise amino acid sequence alignment between recombinant SpEX and SpEX-M.
Attenuated SpEX-M had substitutions of D102A and T125P (highlighted in purple and
orange color, respectively) in the OB-fold domain and T206P and R217A (highlighted in
green and yellow color, respectively) in the sialated glycan binding domain. The herpes
simplex virus (HSV) tag and 6x his tag was annotated with red arrows whereas the protein
domains were annotated with orange arrows.
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Cloning, expression, and purification of recombinant S. pseudintermedius SpEX
Recombinant native and mutant SpEXs with C- terminal 6x histidines (Figure 5.3) were
generated in E. coli and purified under native conditions using HisPur Ni-NTA affinity
chromatography. Both SpEX and SpEX-M expressed well from E. coli and remained
soluble in solution, indicating protein stability with the amino acid substitutions. The
molecular weights of SpEX and SpEX-M determined in western blots were of the
expected sizes (27. 63 and 27.49 kDa, respectively) (Figure 5.4).
SpEX interferes with complement function
Binding of SpEX to human complement C5 was detected using ELISA, wherein
complement component C5 was coated on ELISA plates and binding of recombinant
native and attenuated his-tagged SpEX to C5 was measured using horseradish

Figure 5.4 Western blot of recombinant S. pseudintermedius native and mutant
SpEX detected with HRP-conjugated anti-6xhis
The Molecular weights of recombinant SpEX (rSpEX) and rSpEX-M, after expression in
Tuner ™ (DE3) pLacI E. coli induced by Isopropyl β-D-1-thiogalatopyranoside (IPTG),
determined in western blots were of the expected sizes (27. 63 and 27.49 kDa,
respectively) in the elution fractions (E1 and E2).
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peroxidase (HRP)-conjugated anti-his tag monoclonal antibody. SpEX bound to human
C5 significantly higher, in a dose dependent manner (0.5 with P =0.0171, 1 µg /ml with P
=0.0027, 2 and 4 µg /ml with P <0.0001), than SpEX-M (Figure 5.5, a).
A hemolytic assay was used to evaluate SpEX mediated- inhibition of RBC lysis by
complement. SpEX fixed complement and caused inhibition of hemolysis in a
concentration dependent manner. At concentrations of 0.5, 1, 2 and 4 µg /ml, SpEX
reduced the hemolysis of sensitized bovine erythrocytes compared to the positive control
with P < 0.0001. SpEX at a concentration of 4 µg/ml showed no significant difference in
hemolysis compared with the negative control (Figure 5.5, b)

Figure 5.5 SpEX interferes with complement function
(a) HRP-conjugated anti-6xhis tag monoclonal antibody was used at a dilution of 1/1000
to detect recombinant SpEX bound to human C5. Recombinant SpEX bound
significantly higher to human C5 than recombinant SpEX-M protein (0.5 with P
=0.0171**, 1 µg /ml with P =0.0027**, 2 and 4 µg /ml with P <0.0001****). These values
represent averages from three independent experiments. (*P < 0.05 was considered
significant).
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Figure 5.5 (b). Starting at a concentration of 0.5 µg/ml, SpEX significantly reduced the
hemolysis of sensitized bovine erythrocytes compared to the positive control with P <
0.0001****. SpEX at a concentration of 4 µg/ml showed no significant difference in
hemolysis compared with the negative control. The values represent averages from three
independent experiments. (*P < 0.05 was considered significant).
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SpEX inhibits neutrophil migration
A trans-well neutrophil migration assay was used to determine the inhibitory effect of
recombinant SpEX on neutrophil migration in vitro. Recombinant SpEX at 0.2 µg/ml (at a
concentration selected to assure cells remained viable (Figure 5.8) inhibited the migration
of neutrophils induced by fetal bovine serum compared to SpEX-M at 0.2 µg /ml with P
=0.0001 (Figure 5.6). To validate the results, the viability of neutrophils during
experiments was examined to ensure that killing did not occur at the concentration of
SpEX used.
Attenuated SpEX induces a strong antibody response
Recombinant SpEX-M at 20 µg in 0.5 ml in phosphate buffered saline (PBS) (pH 7.2) was
injected into three clinically normal dogs subcutaneously in the lateral thorax.

Figure 5.6 PMN transmigration assay
Recombinant SpEX at a concentration of 0.2 µg /ml significantly inhibited the migration of
PMNs induced by fetal bovine serum compared to SpEX-M at the same concentration
with P < 0.0001****. The chemotaxis inhibition by culture supernatant of S.
pseudintermedius 06-3228 was significantly higher than SpEX P = 0.0035**. The values
represent averages from three independent experiments. (*P < 0.05 was considered
significant). Data are plotted on the Y axis X 1000.
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Sera were collected from dogs on days -7, 8, 15 and 29 (relative to SpEX-M injections).
IgG reactive with SpEX-M and SpEX was detected by ELISA on day 15 (P < 0.0001) and
at a higher level on day 29 (P < 0.0001) compared to pre-injection control sera (Figure
5.7). Both SpEX and SpEX-M were recognized by dog anti-SpEX-M, confirming that there
were no major antigenic differences between native and mutant SpEX.
SpEX kills canine PMNs and monocytes
Canine PMNs and monocytes harvested from canine blood were highly susceptible to
SpEX with cell permeability induced within 30 minutes in a concentration dependent
manner (50, 25, 12.5, 6.25, 3.12 µg SpEX/ml in PBS, pH 7.2) and by a 1:2 dilution of S.
pseudintermedius strain 06-3228 culture supernatant (Figure 5.8). SpEX-M showed a
diminished effect on cell permeability of canine PMNs (P = 0.0052) (Figure5.8)

Figure 5.7 Dogs injected with SpEX-M developed IgG specifically reactive with
recombinant native SpEX and SpEX-M
Antibodies against S. pseudintermedius native SpEX and SpEX-M were measured using
an indirect ELISA. Recombinant S. pseudintermedius SpEX and SpEX-M proteins were
coated on ELISA plates, then incubated with two-fold serially diluted serum from dogs
vaccinated with the same proteins. High reactivity with SpEX and SpEX-M occurred with
sera collected two weeks after the third injections of SpEX-M (P=0.0001) compared to
pre-injection sera. The values represent averages from three independent experiments.
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Figure 5.8 S. pseudintermedius recombinant SpEX has a cytotoxic effect on canine
monocytes and PMNs
Gating on canine monocytes (green color) and PMNs (red color) was based on side and
forward scatter (shown in dot plot). The mean fluorescent intensity (MFI) of the buffer
control and SpEX-M relative to SpEX was significantly lower in PMN (P < 0.0001****) and
monocyte (P <0.0001****) permeability assays.
The values were calculated based on average values from three independent
experiments (*P < 0.05 was considered significant, **** P <0.0001, **** P =0.0043).
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and monocytes compared to SpEX (P < 0.0001) (Figure 5.8). At SpEX concentrations of
50, 25, 12.5, 6.25 and 3.12 µg/ml, monocyte cell permeability was significantly different
from that of SpEX-M and the negative control (P = 0.0001) (Figure 5.8). However, SpEX
at concentrations of 50, 25, 12.5 and 6.25 µg/ml, had a significant effect on PMN cell
permeability compared to SpEX-M and negative control (P =0.0001) (Figure 5.8).
Canine anti-SpEX-M reduced the effects of SpEX on PMNs and monocytes in vitro
Canine anti-SpEX-M collected after 3rd injection, at a dilution of 1:100 in PBS (pH 7.2),
preincubated with recombinant SpEX at a concentration of 0.2 µg /ml, significantly
reduced the inhibitory effect of rSpEX on leukocyte chemotaxis compared to serum
collected from dogs before SpEX-M injection and control serum with P < 0.0001 (Figure
5.9, a).
In a measure of the protective effect of canine anti-SpEX-M against the native protein,
rSpEX (3.1 µg per ml of PBS) treated with anti-SpEX-M at dilution 1:100 significantly
reduced cell permeability represented by mean fluorescent intensity (MFI) as compared
with that of SpEX treatment alone (Figure 5.9, b)
Discussion
Using mass spectrometry referenced to genomic data, it was possible to identify a new
S. pseudintermedius exotoxin, SpEX, in S. pseudintermedius. SpEX secretion was
confirmed in three S. pseudintermedius strains representing the three clonal complexes
that predominate in the United States (82). SpEX from the most commonly isolated clonal
complex, CC68, was used in this study. However, SpEX is highly conserved among all
three clonal complexes. Although its sequence is unique, this protein has a typical SSL
tertiary structure, shared by S. aureus SSLs and SEIX, consisting of an N-terminal OBfold domain that folds into a five-stranded β-barrel and a C-terminal β-grasp domain.
However, SpEX, in addition to sharing the chemotaxis and complement inhibitory
properties of SSLs, has a cytotoxic effect against monocytes and PMNs
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Figure 5.9 Canine anti-SpEX-M reduced the effects of SpEX on PMNs and
monocytes in vitro
(a) Canine anti-SpEX, collected after three injections, at a dilution of 1:100 in PBS (pH
7.2), preincubated with recombinant SpEX, significantly diminished the chemotaxis
inhibition of SpEX with P < 0.0001****.
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Figure 5.9 (b). Pre-incubation of canine anti-SpEX diluted 1:100 with SpEX resulted in a
significant reduction in MFI as compared with that of SpEX treatment alone. There was
no significant difference between SpEX and SpEX treated with pre-serum. The MFI of
SpEX pre-incubated with anti-SpEX 1:100 relative to SpEX was significantly lower in PMN
(P < 0.0001****) and monocyte (P = 0.012**) permeability assays. The values calculated
were based on average values from three independent experiments (*P < 0.05 was
considered significant).
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These functions likely promote bacterial survival in their hosts and increase the likelihood
of transmission. The attenuated SpEX remained soluble following expression from E. coli
and both SpEX and SpEX-M were recognized by dog anti-SpEX-M. Thus, SpEX-M with
amino acid substitutions in its predicted functional domains did not induce significant
antigenic or conformational changes in the protein, however it showed diminished
immune evasive properties compared to SpEX.
Antibody-mediated toxin neutralization may provide a strategy for immunotherapeutic
treatment and/or prevention of current and recurrent infection (116, 119). Canine
antibodies to SpEX neutralize and diminish its chemotactic inhibitory and cytotoxic effects
on PMNs and monocytes highlighting the potential value of this protein as a component
in a vaccine to prevent or treat S. pseudintermedius infections.
The increased prevalence of multidrug resistant S. pseudintermedius leaves few options
for antimicrobial therapy (82). Therefore, the development of novel strategies to treat this
pathogen are a research priority (82, 142). One alternative approach is the development
of a vaccine that can confer protection or provide effective therapy. However, vaccines in
S. aureus clinical trials have thus far failed to show efficient protection (156). Previous
studies (140-142) concluded that multicomponent vaccines containing a cocktail of
staphylococcal antigens would likely work best in preventing infections caused by S.
aureus. We propose that a potent and effective vaccine against S. pseudintermedius
would involve immunogenic targets, secreted and/or accessible on the surface of the
bacterium, conserved among prevalent strains and that play important roles in virulence,
such as immune evasion. Understanding S. pseudintermedius protein function, surface
accessibility

and

epitope

conservation

is

crucial

for

vaccine

development

against infections caused by this pathogen.
In conclusion, we describe a new exotoxin produced by S. pseudintermedius that binds
to C5, inhibits complement activation and permeabilizes leukocytes. A mutant version of
the protein has reduced cytotoxic effects on dog PMNs and monocytes in vitro. Canine
anti-SpEX produced against an attenuated form of the protein reduced its chemotaxis
inhibition. Therefore, these mutant proteins may serve as important components of a
multivalent vaccine for prophylaxis of S. pseudintermedius infections. By neutralizing
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extracellular toxins responsible for host tissue destruction and immunosuppression, such
a vaccine may help the host immune system control infections.
Future studies might examine potential interactions with TLR as well as regulation of
SpEX expression and the effects of quorum sensing and biofilm on production of the
protein to better understand its role in pathogenesis. In addition, orthologs of SpEX
produced by other members of the Staphylococcus intermedius group should be studied
to determine their role in the virulence of these species.
Materials and Methods
Ethics Statement
Experimental protocols were reviewed and approved by the University of Tennessee
Institutional Animal Care and Use Committee (IACUC) including 2474-0716 for samples
of dog blood and 2572-1217 for producing antibodies in dogs with recombinant protein.
Bacterial strains and plasmids
Log phase bacterial cultures of S.pseudintermedius strains (shown with their sequence
types) 06-3228 (ST68), 08-1661 (ST71) and NA45 (ST84) were analyzed by mass
spectrometry. These strains are representative of the major S. pseudintermedius
genotypes (clonal complexes) most commonly isolated from canine infections in the
United States. A plasmid construct containing a mutated, synthetic S. pseudintermedius
spEX (designed as described below) with BamHI/NotI cloning sites, was obtained
commercially (Genscript Piscataway, NJ USA) (Table 5.1).
Media and growth conditions
Bacterial colonies grown on blood agar plates were inoculated into 5ml of trypticase soy
broth (TSB) (BD Biosciences, San Jose, CA) at 37°C with shaking at 225 rpm. For logphase bacterial cultures, bacteria were grown until an optical density (OD 600) of 0.4-0.6
was reached.
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Table 5.1 Bacteria, plasmids and competent cells used in this study
Plasmid/ Bacteria

Characteristics

Source

pUC19-SpEX-M construct

Cloning plasmid containing synthetic,
attenuated S. pseudintermedius SpEX (717
bp) inserted into MCS of pUC19 between
BamHI and NotI restriction sites

Genscript
Piscataway,
NJ USA

pETBlue-2

Plasmid for T7 promoter based expression of
recombinant proteins with blue/white screening
and C-terminal HSV•Tag and His•Tag
sequences

Novagen,
Madison,
WI

pETBlue-2 SpEX construct

Plasmid containing synthetic S.
pseudintermedius SpEX (716 bp) inserted into
MCS of pETBlue-2 between BamHI and NotI
restriction sites and C-terminal His•Tag
sequences
Plasmid containing synthetic S.
pseudintermedius SpEX-M (717 bp) inserted
into MCS of pETBlue-2 between BamHI and
NotI restriction sites and C-terminal His•Tag
sequences
Competent cells used for cloning pETBlue-2
constructs. Genotype: F- Φ80lacZΔM15 Δ
(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-,
mk+) phoA supE44 thi-1 gyrA96 relA1 λ-.
lacZY deletion mutants of BL21 and a lysogen
of λDE3 that carries a chromosomal copy of the
T7 RNA polymerase gene under control of
the lacUV5 promoter.
Strain representing the most common ST in
the United States (ST68)

This study

Strain representing the most common ST in
Europe and among the three most common in
the United States (ST71)
Strain representing the most common ST in
Asia and among the three most common in the
United States (ST84)

*

pETBlue-2 SpEX-M
construct

DH5α™ E.coli

Tuner™(DE3) pLacI E.coli

S. pseudintermedius 063228
S. pseudintermedius 081661
S. pseudintermedius NA45

This study

Novagen,
Madison,
WI
Novagen,
Madison,
WI
*

**

*University of Tennessee, College of Veterinary Medicine Bacteriology Laboratory.
** A gift of Faye Hartmann of the University of Wisconsin, School of Veterinary
Medicine.
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LC-MS/MS analysis of S. pseudintermedius supernatant
Log phase bacterial cultures of 06-3228, 08-1661 and NA45 were centrifuged at
10,000g for 30 minutes at 4°C and the supernatants were collected and passed through
0.45μm filters (Whatman, GE Healthcare Lifesciences, Pittsburgh, PA). The filtrates
were concentrated using Amicon® Ultra-4 centrifugal filters (EMD Millipore Corp.,
Billerica, MA) and stored at -20°C until further analysis. Samples interrogating S.
pseudintermedius supernatant were prepared for shotgun LC-MS/MS analysis.
Trypticase soy broth (media alone) and bacterial culture supernatant passed through
control Sepahrose beads (without IgG) served as controls. Peptides were separated
and analyzed with a 2-step MudPIT LC-MS/MS protocol (salt cuts of 50mM and 50mM
ammonium acetate) over a 4-hr period then measured with a hybrid LTQ XL-Orbitrap
(Thermo Scientific, Waltham, MA) mass spectrometer (MS). The percent coverage of
detected proteins was calculated as previously described (157).
Bioinformatics analysis
Multiple sequence alignment (MSA) of SpEX proteins from a total of 123 S.
pseudintermedius isolates available in the Genbank database and others sequenced
previously in our lab (7-9) was performed using Geneious 11.0.3 software (107). Protein
Homology/analogY Recognition Engine V 2.0 (Phyre2) was used to develop a S.
pseudintermedius SpEX model (http://www.sbg.bio.ic.ac.uk/phyre2) with alignment
coverage, identity percent and confidence set to 82%, 100% and 40% respectively
(109). The 3DLigandSite online tool (http://www.sbg.bio.ic.ac.uk/3dligandsite/) was used
for binding site prediction (110).
The S. pseudintermedius SpEX sequence was aligned to S. aureus SSL4, SSL5,
SSL11 and SEIX to identify the shared protein domain and secondary structures. We
designed a full-length, attenuated S. pseudintermedius SpEX construct (SpEX-M), with
the following amino acid substitutions: D102A, T125P, T206P and R217A.
Polymerase chain reaction (PCR) amplification of SpEX
DNA was extracted using a MO BIO UltraClean® Microbial DNA Isolation Kit (QIAGEN
Inc.) according to the manufacturer instructions. Oligonucleotide primers (Integrated
DNA Technology, Coralville, USA) (Table 5.2) were designed using the PrimerQuest
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Table 5.2 Primers used to amplify recombinant wild- type and attenuated spEX
from S. pseudintermedius and pUC19-spEX-M plasmid
NotI and BamHI restriction sites are bold and underlined, nucleotide sequences
belonging to SpEX and SpEX-M are show in italics, the primer binding sites are
highlighted in purple color and sequences outside SpEX and SpEX-M (GCATGA) were
used to flank NotI and BamHI recognition sites.

Tool (https://www.idtdna.com/Primerquest/Home/Index) based on the genomic
sequence of S. pseudintermedius strain 06-3228 (9).
The native SpEX open reading frame (ORF) (705bp) excluding N-terminal signal
peptide was amplified from S. pseudintermedius strain 06-3228 genomic DNA and the
mutant SpEX was amplified from a pUC19-spEX-M plasmid (Genscript Piscataway, NJ
USA) (Table 5.1) using taq polymerase (rTaq, Takara).
Cloning, expression, and purification of recombinant native and attenuated SpEX
S. pseudintermedius native and mutant SpEX PCR products were cloned using NotI
and BamHI digested pETBlue-2 (Novagen,) (Table 5.1). The plasmid constructs were
transformed into cloning host DH5-alpha E. coli chemically-competent cells, (Table 5.1)
(New England BioLabs Inc.,) before being transformed into expression host, Tuner ™
(DE3) pLacI E. coli chemically-competent cells (Table 5.1) (Novagen,) by heat shock.
Recombinant S. pseudintermedius native and mutant SpEX expression were performed
from E. coli pETBlue-2 constructs as previously described (17) using LB broth
containing 50µg/ml ampicillin and 20µg/ml chloramphenicol as protein expression
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media. Protein expression was induced by addition of 1 mM Isopropyl β-D-1thiogalatopyranoside (IPTG). Protein extraction was performed using BugBuster
reagent (Novagen) and 100X protease inhibitor (Cocktail Set III, EDTA-Free
Calbiochem,). Recombinant proteins were purified using affinity purification (HisPur™
Ni-NTA Spin Purification Kit, Thermo Scientific). Protein concentrations were
determined using a bicinchoninic acid (BCA) assay (Thermo Scientific).
SDS-PAGE and western blot
SDS-PAGE in 4-12 % polyacrylamide gels (Invitrogen) was used to measure the
molecular weight of expressed recombinant proteins. The resolved protein samples
were blotted onto nitrocellulose membranes (Thermo Scientific). Then the blots were
incubated in 5% (wt/vol) nonfat dried milk powder in 0.05% polyethylene glycol sorbitan
monolaurate (Tween 20) containing phosphate buffered saline (PBS-T) overnight at
4°C. Horseradish peroxidase (HRP)-conjugated anti-6xhis tag monoclonal antibody
(Thermo Scientific) diluted 1:2,000 in 0.05% PBS-T was added to the blocked
membranes and incubated for 1 h with 225 rpm shaking at room temperature. After five
washes with 0.05% PBS-T, bound antibodies were detected using 1-Step™
chloronaphthol substrate solution (Thermo Scientific).
Preparation of canine anti- S. pseudintermedius SpEX
The endotoxin concentration in purified recombinant SpEX-M was measured using a
ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit (Genscript). Recombinant
SpEX-M at 20 µg was diluted in 0.5 cc in phosphate buffered saline (PBS) (pH 7.2) and
injected into three clinically normal dogs subcutaneously in the lateral thorax. Three
injections were given 7 days apart with a control dog receiving PBS (pH 7.2) only. Blood
was drawn on days -7, 8, 15 and 29 (relative to injections) and serum separated.
Enzyme-linked immunosorbent assay
Recombinant SpEX and SpEX-M were coated separately onto ELISA plates (Corning)
at 2µg/ml in PBS. The plates were washed with 0.05% PBS-T and incubated with twofold serial dilutions of serum from dogs (injected with recombinant proteins) for 1 h at
37°C, then bound IgG was detected using HRP-conjugated goat anti-dog IgG-heavy
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and light chain (Bethyl Laboratories, Inc.). ELISA assay plates were washed three
times with PBS-T between all incubations, bound antibodies were detected using TMB
substrate (Thermo Scientific), and reactions were stopped with 0.18 M sulphuric acid
and optical density read at 450 nm on a plate reader (Bio TEK, EL800). The experiment
was repeated a minimum of three times and a p-value of <0.05 was considered
significant for all the experiments unless otherwise stated.
Trans-well assay for neutrophil transmigration
Canine blood was collected from healthy dogs using a sterile blood collection system
with EDTA anticoagulant (BD Vacutainer). Canine neutrophils were isolated according
to O’`Donnell (158), washed several times, and re-suspended in pre-warmed 1ml RPMI
medium.
A neutrophil transmigration assay protocol was used as previously described (159) with
modifications. The assay was performed in 24-well plates with polycarbonate
membrane (3.0 μM pore size and 6.5 mm well diameter) chambers (Corning
Incorporated). Six hundred microliters of Dulbecco's Modified Eagle Medium (DMEM)
with 10% of fetal bovine serum, as a PMN chemoattractant, was placed in each bottom
well. Subsequently, SpEX and SpEX-M treated canine neutrophils (1 × 106), were added
to the top chamber and incubated at room temperature for 6 h. DMEM medium was
used as a negative control. Neutrophil viability and migration to the bottom chamber
was quantified using a Countess TM II FL Automated Cell Counter (Thermo Scientific). In
order to measure the protective effect of anti-SpEX on neutrophil transmigration,
recombinant SpEX was incubated with canine anti-SpEX at a dilution of 1:100 for 30
min at 37°C, then tested with the PMN transmigration assay.
Complement C5 binding assay
Human complement component C5 (Sigma-Aldrich) was coated onto ELISA plates
(Corning) at 2µg/ml in PBS. Recombinant SpEX and SpEX-M were added at 0.5, 1, 2
and 4 µg/ml in PBS (pH 7.2) for 1 h at 37°C, then bound recombinant proteins were
detected using (HRP)-conjugated anti-6xhis tag monoclonal antibody (Thermo
Scientific) at a dilution of 1:1000 in PBS-T (pH 7.2). Bound antibodies were detected as
described above. The experiment was repeated a minimum of three times and a p97

value of <0.05 was considered significant for all the experiments unless otherwise
stated.
Complement mediated hemolysis assay
A hemolysis assay was performed to determine the ability of recombinant SpEX to
inhibit complement function. Bovine erythrocytes, collected in EDTA from clinically
normal cattle, were washed in PBS and sensitized to complement by incubation with
rabbit IgG fraction anti-bovine red blood cells (ICN Cappel) diluted 1:25, for 30 min at
37°C with gentle mixing. Dog serum diluted 1:4 was pre-incubated with 0.5, 1, 2 and 4
µg/ml of recombinant native SpEX for 30 min at 37°C with gentle shaking (100 rpm).
One hundred microliters of sensitized bovine RBCs were added to all samples including
positive and negative controls and incubated under the same conditions for an
additional 30 min. After centrifugation at 4200 ×ɡ for 5 min, the absorbance of the
supernatant was measured at 450 nm. Heat-inactivated serum mixed with PBS (pH 7.2)
was used as a negative control and normal dog serum, diluted 1:4 was used as a
positive control.
PMN and monocyte permeability assay
PMNs and monocytes were separated as previously described. PMNs and monocytes
were incubated with two- fold serial dilutions of recombinant proteins (SpEX or SpEX-M)
from concentrations of 50 µg to 1.6 µg in a volume of 500 μl of RPMI medium
supplemented with 10% fetal bovine serum in an incubator with 5% CO2 for 30 min. The
supernatant of S. pseudintermedius strain 06-3228 was harvested at log phase to test
the toxic effect of secreted, native SpEX. PMNs and monocytes were stained with 1 µl
Sytox green (Life Technologies, Inc.) for 30 min, then washed twice with PBS (pH 7.2)
and analyzed using a flow cytometer (Attune acoustic focusing cytometer) by gating
separately on PMNs and monocytes.
To evaluate the protective effect of canine anti-SpEX-M on PMNs and monocytes,
recombinant S. pseudintermedius SpEX, at concentration of 3.1 µg diluted in 1ml of
PBS (pH 7.2) was incubated for 30 minutes at 37ºC with serum from SpEX-M injected
dogs. The cell death cut-off used for flow cytometry analysis was established using
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leukocytes incubated without SpEX. Mean fluorescent intensity was measured from all
gated cells.
Statistical analysis
Each experiment was repeated at least three times with a minimum of duplicate
samples. Data analysis was conducted for each response variable using ANOVA
methods, with treatment and dose as the independent variables. Diagnostic analysis
was performed to check the model assumptions for normality and equal variance.
Multiple comparisons were made with tukey's adjust. Significance was identified at
p<0.05. All analysis was conducted in SAS 9.4 for Windows x64 from SAS Institute
(Cary, NC) and some graphical outputs were generated by GraphPad Prism software
(Version 7, GraphPad Software Inc.).
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CHAPTER 6
IDENTIFICATION, CLONING AND CHARACTERIZATION OF 5′NUCLEOTIDASE PRODUCED BY STAPHYLOCOCCUS
PSEUDINTERMEDIUS
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Abstract
S. pseudintermedius is a major opportunistic bacterial pathogen and the leading cause of
pyoderma in dog. It is often associated with infections of the urinary system, wound and
sometimes infects people. Widespread antimicrobial resistance has made the
development of alternative treatments a high priority. The development of a
staphylococcal vaccines, however, has proven challenging. Identification of virulence
factors that inhibit phagocytosis and avoid innate immunity may play a significant role in
preventing or treating infection with S. pseudintermedius. In this study, we identified a
putative 5′-nucleotidase provisionally named SpAdsA, an S. pseudintermedius cell- wall
protein encoded by SpAdsA. SpAdsA shares approximately 52 % identity with the
orthologous protein of Staphylococcus aureus and 20 % identity with that of
Streptococcus suis type2. It catalyzes the dephosphorylation of adenosine mono- and
triphosphates producing adenosine that suppresses phagocytosis and facilitates bacterial
survival. Attenuation of this enzyme with critical amino acid substitutions nearly eliminated
its

hydrolytic

activity.

Exogenous

adenosine

inhibited

phagocytosis

of S.

pseudintermedius by canine neutrophils and monocytes. Conversely, the addition of
SpAdsA inhibitor or A2A adenosine receptor antagonist impaired the capacity of S.
pseudintermedius to escape from killing by phagocytic cells. Antibody against SpAdsA-M
was developed in clinically healthy dogs and the neutralizing effect of those antibodies
was evaluated. Taken together, these results suggest that SpAdsA likely plays an
important role in S. pseudintermedius virulence and that attenuated SpAdsA may be an
important candidate for inclusion in a vaccine against S. pseudintermedius infections.
Keywords: 5′-nucleotidase, S. pseudintermedius, SpAdsA, PMNs, immune evasion,
virulence, vaccine
Introduction
S. pseudintermedius is an opportunistic pathogen. It causes disease when the host's
immune system is compromised or an external skin barrier breach occurs, such as
wounds and surgical procedures or other factors that predispose the host to atopic
dermatitis. S. pseudintermedius is often isolated as a common inhabitant of the skin and
mucosa from noses, body, forehead, groin and anal region of healthy dogs and cats (6).
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S. pseudintermedius is a coagulase-positive staphylococci (CPS) with a variety of
virulence factors, some of them are similar to the ones described for S. aureus (15) such
as proteases, leucocidin (17) and protein A (16, 21). S. pseudintermedius can produce
various toxins including leukotoxins (17) and enterotoxins that cause substantial damage
to host tissue and adversely affect host defenses (16, 17).
Methicillin resistance and associated multidrug resistance to antimicrobials available to
veterinarians is common among S. pseudintermedius and presents a treatment challenge
(9). The development of alternative therapies is, therefore, a high priority.
There are no licensed S. pseudintermedius vaccines. This is likely due to a lack of
information about S. pseudintermedius protein functions, surface accessibility and
epitope conservation. Information about other species of bacteria, especially
staphylococci, is useful in the development of a S. pseudintermedius vaccine, however,
this species is unique with regard to its disease presentation, genetic structure and
composition, host range, and the virulence proteins it produces. Whole bacterial
staphylococcal vaccines have not been efficacious. With an estimated greater than 2,000
different proteins produced by each bacterium, it is essential to identify and direct the
immune response against the most important antigen targets. However, many of these
proteins are potentially harmful to animals and must be attenuated to make them safe
without eliminating epitopes that induce a protective immune response. Effective
staphylococcal defenses are in the bacteria capacity to neutralize and/or destroy key
components of their host immune system.
Upon infection or cell damage, high amounts of adenosine triphosphate (ATP), adenosine
monophosphate (AMP), adenosine diphosphate (ADP) are released from damaged cells,
which serve as mediators of inflammation through purinergic cell surface receptor
signaling (69, 70). As a protective mechanism to prevent excessive damage to host
tissue, adenosine counteracts the ATP's effect by adenosine receptor stimulation to
suppress the pro-inflammatory response. Four adenosine receptors have been
described: A1R, A2AR, A2BR and A3R. Neutrophils express all four adenosine receptors (71,
72). They are the most abundant mammalian leukocytes and form a key component of
the innate immune response against staphylococcal infection (73, 74).
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In mammals, extracellular nucleotide and adenosine concentrations are controlled by
nucleotide metabolizing enzymes. In this two-step process, CD39 catalyzes
dephosphorylation of ATP and ADP to produce AMP. 5′-nucleotidase (CD73) contains a
characteristic two-signature sequence domain and hydrolyzes AMP into adenosine (74,
75). Some bacilli employ adenosine synthase to interfere with the balance between
extracellular nucleotides and adenosine by perturbing the adenosine level beyond the
physiological range (76, 77). Extracellular 5′-nucleotidases have been identified in
Staphylococcus aureus and Streptococcus suis type 2 (75, 78) and shown to play an
important role in evasion of the innate immune response.
Thammavongsa et al, (75) demonstrated that S. aureus may avoid phagocytic clearance
in blood and identified 5′-nucleotidase (also named adenosine synthase A (AdsA)), a cell
wall–anchored enzyme that converts adenosine monophosphate to adenosine, as a
major virulence factor (72, 75). S. aureus AdsA has two signature sequences, the first
nucleotidase signature sequence contain residues essential for divalent metal cation
binding (75), whereas the second signature sequence is responsible for the hydrolytic
activities of AdsA (75).
In this study, we identified a novel cell wall-anchored 5′-nucleotidase in S.
pseudintermedius (SpAdsA) that has no more than 52 % identity with other bacterial
adenosine synthase genes, but which contains conserved functional domains.
Adenosine synthase activity has not been previously described in S. pseudintermedius or
any members of the Staphylococcus intermedius group. The specific objectives of this
study were to characterize the immunobiological properties of S. pseudintermedius
SpAdsA and attenuated (reduced toxicity) SpAdsA (SpAdsA -M) by measuring their
inhibitory effects on phagocytosis. Antibody against SpEX-M was developed in clinically
healthy dogs and the neutralizing effect of those antibodies was evaluated.
Results
Bioinformatics Analysis and S. pseudintermedius SpAdsA Characteristics
S. pseudintermedius SpAdsA showed significant homologies to members of the 5′nucleotidase/apyrase protein family (Interpro accession number: IPRO006179) with two
characteristic

domains.

Dimetal-containing

phosphoesterases

(DMPs)

(Interpro
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accession number: IPRO29052) are between position 147 and 401 with two domain
signature sequences D1 (ILHTNDIHGRM) and D2 (YDAMTAGNHEFD) (Figure 6.1) and
a 5′-nucleotidase C-terminal domain (Interpro accession number: IPRO008334) between
positions 447 and 599 (Figure 6.1). Furthermore, the protein sequence contains a
predicted N-terminal signal peptide sequence from positions 1 through 24 and a LPXTG
cell wall anchor sequence between positions 748 and 752 (Figure 6.1).

Only limited identity of sequence was found with S. aureus AdsA (52.4%), Enterococcus
fecalis 5′-nucleotidase (36.0%), S. pyogenes S5nA (20.1%) and S. suis Ssads (20.0%)
(Figure 6.2). No other species of bacteria with homologous proteins were identified in the
database.

Figure 6.1 schematic presentation of SpAdsA of S. pseudintermedius
A BLAST search of the GenBank database revealed related putative nucleotidases in
other pathogenic bacterial species within the Staphylococcus intermedius group including
Staphylococcus delphini (90.8% amino acid identity), Staphylococcus intermedius (88.5%
amino acid identity) and Staphylococcus cornubiensis (87.8% amino acid identity).
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Figure 6.2 Phylogenetic tree of 5′-nucleotidase
The rooted phylogenetic tree (unweighted pair group method with arithmetic mean) was
generated with Geneious version 9.1.3 using complete 5′-nucleotidase protein sequences
from each bacterial species. The gap open penalty was set on 12 and BLOSUM62 was
used as the cost matrix.
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Multiple sequence alignment (MSA) analysis showed that SpAdsA is conserved among
S. pseudintermedius strains including 06-3221, 08-1661and NA45 that represent the
major sequence types occurring in the United States as determined by multilocus
sequence typing (82). The 5′-nucleotidase gene contains an open reading frame in S.
pseudintermedius that is 2,343 bp in length with amino acid identities over 99.4 %
between strains.
Bioinformatics analysis of S. pseudintermedius SpAdsA showed that aspartic acids (D)
(positions 154 and189), histidine (H) (positions 156, 318, 354 and 356) and asparagine
(position 221) within the SpAdsA signature sequences are essential for divalent metal
cation binding. Based on the previously reported Gram-positive bacterial nucleotidases
and our 3D model we designed mutant protein SpAdsA (SpAdsA-M) where aspartate
(position 154 and 225) and histidine (position 156 and 222) were substituted at these
positions in S. pseudintermedius 08-1661 SpAdsA referenced to Genbank accession No:
ANS88668.1 (Figure 6.3).

Figure 6.3 three-dimensional model of S. pseudintermedius SpAdsA protein
The critical amino acids ASP at positions 154 (cyan), HIS at positions 156 (blue), HIS at
positions 222 (light green), ASP at positions 225 (orange) within the SpAdsA signature
sequences D1 (ILHTNDIHGRM) and D2 (YDAMTAGNHEFD) were substituted with
alanine to produce the mutant protein.
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Cloning, expression and purification of recombinant S. pseudintermedius
SpAdsA
SpAdsA is predicted to have an N-terminal signal sequence and C-terminal sortase
anchoring domain. Recombinant SpAdsA proteins lacking those sites were produced to
facilitate a study of the mature protein. The sizes of recombinant native and mutant
SpAdsA were 55.8 kDa and 55.4 kDa respectively, as determined by western blot using
monoclonal antibody directed against the tag. SpAdsA -M expressed well from E. coli and
remained soluble in solution, indicating protein stability with the amino acid substitutions
(Figure 6.4).
S. pseudintermedius 5′-nucleotidase synthesizes adenosine
Tryptic digests of surface proteins of S. pseudintermedius 06-3228 showed hydrolytic
activity that released adenosine from AMP and ATP (Figure 6.5). Similar activity was
obtained with recombinant SpAdsA which harbors a domain with the two signature
sequences, ILHTNDIHGRM and YDAMTAGNHEFD. The total release of inorganic
phosphate (Pi) by recombinant SpAdsA (mean Pi moles phosphate in 50 µl = 7998.32)
as well as 06-3228 tryptic digest (mean Pi moles phosphate in 50 µl = 6688.42) from 50
µl of 1mM ATP and AMP was significantly higher than that from the mutant protein (mean
Pi moles phosphate in 50 µl = 555.79) (p<0.001) (Figure 6.5). This suggests that the two
signature sequences (D1 and D2) are critical for enzymatic activity in S. pseudintermedius
like that of S. suis type 2 (78). Together these results confirm that SpAdsA is capable of
hydrolyzing ATP and AMP to produce adenosine.
SpAdsA-M stimulates specific antibody responses against 5′-nucleotidase in
dogs
ELISA analysis of sera obtained from dogs on days −7, 8, 15, and 29 (relative to the first
injection of SpAdsA-M) demonstrated that antibodies to SpAdsA and SpAdsA -M (Figure
6.6) on day 15 were detected and on day 29 were found to be at the highest level (P <
0.0001) compared to the sera pre-injection control.
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Figure 6.4 Western blot of recombinant S. pseudintermedius native and mutant
SpAdsA detected with HRP-conjugated anti-6xhis.
The Molecular weights of recombinant SpAdsA and SpAdsA -M, after expression in
Tuner ™ (DE3) pLacI E. coli induced by Isopropyl β-D-1-thiogalatopyranoside (IPTG),
determined in western blots were of the expected sizes (55.8 and 55.4 kDa,
respectively) in the elution fractions (E1 and E2). C stand for elution control.

Figure 6.5 S. pseudintermedius 5′-nucleotidase synthesizes adenosine
The total release of inorganic phosphate (Pi) by 5’ nucleotidase as well as 06-3228 tryptic
digest in P moles from 50 µl of 1mM ATP and AMP was significantly higher than that from
the mutant version of 5’ nucleotidase. The mean IP release (+standard error) following
treatment (a) and protein treatment (b). N=12 per adenosine mono- and triphosphates
group and N=9 per protein treatment. Different letters above the bar indicate significant
differences among treatments (p<=0.001).
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Figure 6.6 Dogs injected with SpAdsA-M developed IgG specifically reactive with
recombinant native SpAdsA and SpAdsA-M
Antibodies against S. pseudintermedius native SpAdsA and SpAdsA-M were measured
using an indirect ELISA. Recombinant S. pseudintermedius SpAdsA and SpAdsA-M
proteins were coated on ELISA plates, then incubated with two-fold serially diluted serum
from dogs vaccinated with the same proteins. High reactivity with SpAdsA and SpAdsAM occurred with sera collected two weeks after the third injections of SpAdsA-M (P
<0.0001) compared to pre-injection sera. The values represent averages from three
independent experiments.
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SpAdsA inhibits phagocytosis of S. pseudintermedius in canine blood
To investigate the potential immune evasive attributes of SpAdsA, the effect of adenosine
on the survival of S. pseudintermedius strains 06-3228 and 08-1661 in canine blood was
examined. As shown (Figure 6.7) adenosine at a concentration of 15 µM significantly
promoted S. pseudintermedius strains 06-3228 survival greater than 06-3228 without
treatment at 60 minutes (p<0.0001), 90 minutes (p<0.0001) and at 120 minutes
(p=0.0046). For S. pseudintermedius strains 08-1661 adenosine at the same
concentration significantly promoted bacterial survival compared to bacteria without
treatment at 60 minutes (p<0.0001) and 90 minutes (p<0.0001) and there was no
significance difference at 120 minutes. Conversely, 5′-(α, β-methylene) diphosphate at
concentration of 500 µM, a 5′-nucleotidase inhibitor (also called ADP analog and CD73
inhibitor), significantly diminished the ability of staphylococci to escape from phagocytic
killing compared to 06-3228 without treatment at 60 minutes, 90 minutes and 120 minutes
(p<0.0001). For 08-1661, CD73 inhibitor treatment showed significant difference at 60
minutes (p=0.0002), 90 minutes (p=0.0146) and 120 minutes (p=0.0034) (Figure 6.7).
These results suggest that extracellular adenosine produced by SpAdsA inhibits
phagocytic cell activity and promotes bacterial survival.
To determine the role of A2A receptors on canine PMNs in the signaling pathway of
adenosine we performed pharmacological inactivation of A 2AR using the A2A receptor
antagonist ZM241385. With ZM241385 (1 µM), survival of S. pseudintermedius 06-3228
and 08-1661was significantly decreased at all of time points (06-3228: p<0.0001; 081661: p<0.0001) compared to the same bacterial strains without the antagonist (Figure
6.7). Collectively, these results showed that adenosine has an inhibitory effect on
phagocytosis, and it mediates its inhibitory signals through A2A receptors on the surface
of canine neutrophils.
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Figure 6.7 SpAdsA inhibits phagocytosis of S. pseudintermedius in canine blood
through A2A receptors
The difference between S. pseudintermedius survival in canine blood from those with
different treatments (exogenous Adenosine (15µM), CD73 inhibitor (500µM) and
ZM241380 (1µM)) was calculated at different time points (60 minutes, 90 minutes and
120 minutes) N=3 per treatment. * Above the lines indicates a significant difference
between the treatments at the corresponding time. For S. pseudintermedius 06-3228 **
(p=0.0046) and **** (p<0.0001). For S. pseudintermedius 08-1661 * (p=0.0146), **
(p=0.0034), *** (p=0.0002) and **** (p<0.0001).
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Dog anti SpAdsA -M reduce the effect of SpAdsA on phagocytosis in vitro
Pre-incubation of S. pseudintermedius with dog anti SpAdsA -M at dilutions 1:10 and
1:100 in PBS and bacterial survival assay in dog blood was performed as previously
mentioned.

Dog

anti-

SpAdsA-M

significantly

increased

phagocytosis

of S.

pseudintermedius 06-3228 than 06-3228 alone in dog blood after incubation periods of
60 minutes, 90 minutes and 120 minutes (Figure 6.8).
Discussion
This study showed how S. pseudintermedius modulates neutrophil function by perturbing
adenosine levels using SpAdsA residing on its cell wall. It demonstrates that recombinant
SpAdsA and S. pseudintermedius cell wall proteins containing SpAdsA hydrolyze ATP
and AMP generating inorganic phosphate and adenosine. A search of the GenBank
database for SpAdsA protein in the other three members of the Staphylococcus
intermedius group (SIG) found that 5′-nucleotidase produced by members of this group
share over 81% amino acids identity. Furthermore, we found SpAdsA share no more than
52% amino acid identity with proteins produced by S. aureus, Enterococcus and
Streptococcal species.

Adenosine exerts an immunosuppressive effect through

interaction with purinergic receptor 1 during infections (69, 70). Purinergic receptors are
specific for extracellular purines (adenosine, ADP, and ATP) and pyrimidines (UDP and
UTP) and are conserved among mammalian cell types (69, 70).
Neutrophils play a crucial role as professional phagocytes in the host defense against
pathogens. They produce adenosine and can respond to it via G-protein coupled
receptors expressed on their surface in a dose dependent manner (160). Extracellular
adenosine is essential for the elimination of inflammation but it is also harmful to build up
high adenosine concentrations (161, 162). Disturbance of the immune homeostasis
maintained by adenosine through perturbing its level is likely to aﬀect immune response
of the host during infection. At low adenosine concentration, A1 and A3 receptor subtypes
bound with adenosine stimulate neutrophil chemotaxis and
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Figure 6.8 Dog anti SpAdsA -M reduce the effect of SpAdsA on phagocytosis in
vitro
The difference between S. pseudintermedius survival in canine blood from those with
different treatments (dog anti SpAdsA -M at dilutions 1:10 and 1:100 in PBS and control
serum at the same dilutions) was calculated at different time points (60 minutes, 90
minutes and 120 minutes) N=3 per treatment. * Above the lines indicates a significant
difference between the treatments at the corresponding time. * (p=0.0241), ** (p=0.0083),
*** (p=0.0019) and **** (p<0.0001).
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phagocytosis while at higher levels adenosine exerts its inhibitory effect through A 2A and
A2B receptors to inhibit neutrophil trafficking, oxidative burst, and release of inflammatory
mediators (160). Eppell et al (76) showed that adenosine equally inhibits IgG Fc and
complement-mediated phagocytosis in cultured human peripheral blood derived
macrophages.
SpAdsA was considered a good candidate for producing adenosine synthase due to the
presence of conserved domains associated with this enzymatic activity in other species
of bacteria. Roche et al (163) showed that S. aureus 5’ nucleotidase has a crucial role in
invasion. Thammavongsa et al. (75) further distinguished a fundamental role for S. aureus
5’ nucleotidase in disease. Previous studies demonstrated the importance of S. suis type
2 adenosine synthase (78) but there have not been any reports on immune evasive
attributes of 5’ nucleotidase produced by S. pseudintermedius or studies of it with canine
phagocytes. Native and mutant 5’ nucleotidase proteins excluding signal peptides and
anchoring sequences were used for this study because the full length expressed proteins
were not readily soluble in aqueous solution and would not represent mature proteins
(78). Enzymatic inhibition using an ADP analogue or A2 receptor antagonist significantly
reduced bacterial survival in dog blood suggesting that S. pseudintermedius SpAdsA
plays an important role in canine pathogen immune evasion and may serve as an
important candidate target for novel anti-infective drugs and vaccines against canine
pyoderma.
We used an A2 receptor inhibitor to determine if adenosine signaling occurs through the
A2 receptor in canine cells and found that the addition of ZM241385 stimulated phagocytic
cell activities against S. pseudintermedius. This is consistent with the finding of Jordan et
al (164) although they used the selective adenosine A2 agonist CGS-21680 that activated
A2 receptors and reduced cardiac reperfusion injury and infarction size (165-169) by
inhibiting neutrophil accumulation and superoxide anion production in a canine model of
ischemia and reperfusion.
The present study revealed the diminished ability of canine blood to kill S.
pseudintermedius in the presence of exogenous adenosine. Conversely, addition of ADP
analogue or ZM241385 prevented S. pseudintermedius escape from phagocytic killing
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which is consistent with the findings of Barletta et al (160) and Jordan et al (164) studying
ischemia and perfusion in a canine model using, S.suis type2 SasH (78) and S. aureus
AdsA (75), respectively.
These results indicate that SpAdsA plays an important role in promoting S.
pseudintermedius survival and inhibiting PMN phagocytosis and killing activity by the
synthesis of adenosine. The production of neutralizing antibody in healthy dogs suggests
that attenuated, non-toxic and immunogenic recombinant protein produced in this study
is a good candidate against S. pseudintermedius infection.
Materials and Methods
Ethics Statement. The University of Tennessee Institutional Animal Care and Use
Committee (IACUC) has reviewed and approved experimental protocols, including 24740716 for samples of dog blood and 2572-1217 for producing antibodies in dogs with
recombinant protein.
Bacterial strains and plasmids
The S. pseudintermedius strains, the most common sequence (ST) in the United States,
were used in this study (82, 84, 114), included 06-3228 (ST68), 08-1661 (ST71) and NA45
(ST84) (82, 84, 114). Strains 06-3228 and 08-1661 were isolated at the University of
Tennessee, College of Veterinary Medicine Bacteriology Laboratory. Strain NA45 was a
gift of Faye Hartmann of the University Of Wisconsin School Of Veterinary Medicine.
Plasmid construct pMA-RQ-Bs- M Ado

370-1868,

containing a mutated synthetic S.

pseudintermedius SpAdsA gene with BamHI/NotI cloning sites was obtained
commercially (Invitrogen™ GeneArt™ Gene Synthesis - Thermo Fisher Scientific).
Bioinformatics Analysis and S. pseudintermedius 5′-nucleotidase characteristics
Rooted phylogenetic tree (UPGMA (unweighted pair group method with arithmetic mean))
of 5′-nucleotidases was generated with Geneious version 9.1.3 (107) using complete
protein sequences of SpAdsA (S. pseudintermedius 08-1661, ANS88668.1 ), S5nA (S.
pyogenes, AAK33792)(170), AdsA (S. aureus, ESR29110)(75), Ssads (S. suis,
YP001197640)(78), 5′-nucleotidases (Staphylococcus delphini, WP_096556274.1), 5′nucleotidases

(Enterococcus

faecalis,

WP_010714156.1)

and

5′-nucleotidases
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(Staphylococcus intermedius,, WP_086428047.1). Multiple sequence alignment of S.
pseudintermedius 5′-nucleotidase proteins was performed. The bacterial localization
prediction tool, PSORTb version 3.0.2 (available at http://www.psort.org/psortb/) (108)
was used to predict the topology and domain structure of SpAdsA protein. Protein
modeling and binding site prediction was performed using Phyre2 web portal (available at
http://www.sbg.bio.ic.ac.uk/phyre2/)

(109)

and

3DLigandSite

(available

at

http://www.sbg.bio.ic.ac.uk/3dligandsite/)(110).
Polymerase chain reaction (PCR) amplification of the wild and mutant SpAdsA
gene from S. pseudintermedius
Single bacterial colony of S. pseudintermedius strain 08-1661 obtained from blood agar
plates were grown in tryptic soy broth (TSB) (Becton, Dickinson and Co., Sparks, MD) at
37°C with 225 rpm shaking. MO BIO UltraClean® Microbial DNA Isolation Kit (QIAGEN
Inc. Cat No.12224-50) was used to extract the bacterial DNA according to the
manufacturer instructions. Oligonucleotide primers with BamHI and NotI restriction sites
(underlined)

were

designed

using

the

PrimerQuest

Tool

(https://www.idtdna.com/Primerquest/Home/Index) based on the complete genome
sequence of S. pseudintermedius strain 08-1661(9).
Primers for the amplification of native SpAdsA were
W-Ado-Forward: GCATGAGGATCCGAAACGACTGCAACGCATAC and
W-Ado-Reverse: GCATGAGCGGCCGCTCCACCTGAAGCTGTAAAGTC.
Primers for amplification of mutant SpAdsA were
M-AdoForward: GCATGAGGATCCATGTTAAGATTGTCGGCTAAAAAAG and
M-AdoReverse: GCATGAGCGGCCGCTCCACCTGAAGCTGTAAAGTC.
The native SpAdsA open reading frame (ORF) (1539 bp) without the regions encoding
the predicted N-terminal signal and C-terminal sortase anchoring sequence was amplified
from 60 ng of genomic DNA of S. pseudintermedius 08-1661 by 35 cycles of PCR with
rtaq polymerase (Takara, Cat No. R004) at an annealing temperature of 55 ºC using
primer W-Ado-Forward and W-Ado-reverse. The ORF of mutant SpAdsA (1536bp) was
excised from pMA-RQ-Bs- M Ado plasmid using BamHI- NotI restriction enzymes.
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Cloning and expression of recombinant wild and mutant SpAdsA of S.
pseudintermedius 08-1661
The PCR products of wild and mutant SpAdsA were digested with the restriction enzymes
BamHI and NotI and purified using QuickClean II Plasmid Miniprep Kit (Genscript, Cat
No. L00420) according to the manufacturer instructions. Purified product was ligated into
pETBlue™-2 (Novagen, WI. USA), transformed into DH5-alpha E. coli and plated on LB
agar plates with 100 µg/mL ampicillin, 80 µg/mL X-gal and 50µM IPTG (Teknova, Cat No.
L1925). For screening the clones containing recombinant plasmid, X-gal chromogenic
substrate was added to the agar plates. The recombinant plasmid was extracted using
GeneJET

Plasmid

Miniprep

Kit

according

to

the

manufacturer

instructions

(ThermoFisher, Cat No. K0502). The presence of the cloned fragment was confirmed by
PCR. pETBlue™-2 constructs were transformed in Tuner ™(DE3) pLacI E. coli
chemically-competent cells (Novagen, Cat No .70623) by heat shock and plated on LB
agar containing 50µg/ml ampicillin (Sigma-Aldrich, Cat No. A5354) and 20µg/ml
chloramphenicol (Sigma-Aldrich, Cat No. C0378). A single colony was used to inoculate
LB broth containing 50µg/ml ampicillin and 20µg/ml chloramphenicol and the broth was
incubated overnight at 37ºC with shaking at 225 rpm. Fresh LB medium containing
50µg/ml ampicillin and 20µg/ml chloramphenicol was inoculated at a 1:100 dilution and
grown until an optical density (OD

600)

of 0.4-0.6 was reached then protein expression

was induced by addition of 1 mM isopropyl β-D-1-thiogalatopyranoside (IPTG) for 4 hr at
30ºC with shaking at 225 rpm.
A suspension of IPTG-induced Tuner cell bacteria (100 ml) was centrifuged at 12000 xg
for 5 min. Bacteria were suspended in 5 ml of protein extraction reagent (BugBuster,
Novagen Cat No. 70584) and 20 µl 100X Protease Inhibitor Cocktail Set III, EDTA-Free
(Calbiochem, Cat No. 539134), incubated for 30 min at 37ºC in a shaking incubator at
225 rpm, and centrifuged at 12,000× g for 45 min at 4°C.
Recombinant protein was purified using a HisPur™ Ni-NTA Spin Purification Kit
(Thermo Scientific, Cat No. 88228) according to the manufacturer instructions. Protein
concentrations were determined with the Pierce™ BCA Protein Assay Kit (Thermo
Scientific, Cat No. 23225).
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SDS-PAGE and Western blot
Protein samples were resolved by SDS-PAGE in 4-12 % polyacrylamide gels (Invitrogen,
Cat No. NP0322BOX) and electrophoretically transferred onto a nitrocellulose membrane
(Thermo Scientific, Cat No. 77010). Then the blots were incubated overnight in 5%
(wt/vol) nonfat dried milk powder in 0.05% polyethylene glycol sorbitan monolaurate
(Tween 20) containing phosphate buffered saline (PBS-T) at 4°C. Horseradish
peroxidase (HRP)-conjugated anti-6xhis tag monoclonal antibody (Thermo Scientific, Cat
No.

MA1-21315-HRP) diluted 1:2,000 in 0.05% PBS-T was added to the blocked

membranes and incubated for 1 h with 225 rpm shaking at room temperature. After five
washes with 0.05% PBS-T, bound antibodies were detected using 1-Step™
chloronaphthol substrate solution (Thermo Scientific, Cat No. 34012).
Adenosine Synthase Activity
Overnight cultures of S. pseudintermedius 06-3228 and 08-1661 were centrifuged and
washed twice with phosphate buffer saline (PBS) and then suspended in 1 ml digestion
buffer (0.6 M sucrose buffered with 50 mM Tris, pH 7.5) (74) containing 200 µg trypsin
from porcine pancreas (Sigma-Aldrich, Cat NO. T4799). Bacteria were digested with
trypsin for 1.5 h at 37°C, then the supernatant containing S. pseudintermedius SpAdsA
was obtained after centrifugation at 10,000xg for 5 minutes at 4°C. Four ml of S.
pseudintermedius tryptic digest and recombinant SpAdsA protein at 0.15 µg/ ml were
suspended in 500 µL TM buffer (50 mM Tris-HCL [pH 7.5], 5 mM MnCl2), then hydrolysis
of ATP (Sigma-Aldrich, Cat NO. A26209) and AMP (Sigma-Aldrich, Cat NO. 01930) was
carried out in the presence of 1 mM nucleotide at 37°C for 15 minutes. Inorganic
phosphate (IP) release was measured using a malachite green phosphate kit according
to the manufacturer protocol (Sigma-Aldrich, Cat NO. MAK307).
Production of antibodies against recombinant S. pseudintermedius SpAdsA
Recombinant SpAdsA-M was injected into three clinically normal dogs at 100 μg/0.5 ml
in PBS (pH 7.2) through the subcutaneous route in the lateral thorax. For a total of three
injections with a control dog receiving PBS (pH 7.2) only, injections were given once every
7 days. Blood (6 ml) was collected 4 times on days −7, 8, 15 and 29 from a jugular vein
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using a 20 g needle and 12 cc syringe. The collected blood was left undisturbed at room
temperature for 30 min followed by centrifugation at 2,000 x g for 10 min in a refrigerated
centrifuge.
Enzyme-linked immunosorbent assay
To detect a specific antibody response against SpAdsA- M in injected dogs,
recombinant S. pseudintermedius SpAdsA and SpAdsA –M were coated separately onto
ELISA plates (Corning, Cat No. 3590) at 2μg/ml in PBS (pH 7.2). The plates were washed
with 0.05% PBS-T and incubated with two-fold serial diluted serum from dogs (injected
with recombinant proteins) for 1 h at 37°C, then bound IgG was detected using HRPconjugated goat anti-dog IgG heavy and light chain (Bethyl Laboratories, Inc. Cat No.
A40-123-1). ELISA assays plates were washed three times with PBS-T between all
incubations, bound antibodies were detected using TMB substrate (Thermo Scientific,
Cat No. N301), reactions were stopped with 0.18 M sulphuric acid and optical density
read at 450 nm on a plate reader (Bio TEK, EL800). The experiment was repeated a
minimum of three times and a p-value of <0.05 was considered significant for all the
experiments unless otherwise stated.
Bacterial survival in blood
Overnight cultures of S. pseudintermedius 06-3228 and 08-1661 were diluted 1:100 into
fresh TSB and grown for 3 hours at 37°C. Staphylococci were centrifuged 9000 x g,
washed twice, and diluted in PBS to yield an optical density (OD 600) of 0.5. Then 100 µl
of 4× 106 CFU per ml of bacteria were mixed with 500 µl of fresh canine blood, collected
in EDTA. The samples were incubated at 37°C with 100 rpm shaking and harvested at
60, 90 and 120 minutes. They were incubated on ice for 30 minutes in 1 ml of Red Blood
Cell Lysing Buffer Hybri-Max™ (Sigma-Aldrich, Cat NO. R7757), then bacteria were
pelleted at 9,000 x g at 4°C and plated on tryptic soy agar (TSA) for enumeration of viable
bacteria. To determine the effect of canine anti SpAdsA- M on phagocytic cells, S.
pseudintermedius was incubated for 30 minutes at 37ºC with serum from SpAdsA- M
injected dogs at two different dilutions 1:10 and 1:100 in PBS (pH 7.2) with serum from
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saline injected dogs at the same dilutions was used as a control. The experiment was run
in duplicate and a p-value of < 0.05 was considered significant.
Statistical Analysis
Data were analyzed using general liner modes with treatment, protein and time as the
independent variables while inorganic phosphate (IP) release, mean fluorescence
intensity (MFI) and colony forming units per ml (CFU ml-1) were used as response
variables, respectively. Multiple comparisons were performed with Tukey’s adjustment.
Statistical significance was identified at the significant level of 0.05. Rank transformation
on response variables were conducted when the normality assumption was violated. All
analyses were conducted using PROC mixed in the SAS system for Windows version 9.4
(SAS Institute Inc., Cary, NC).
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CHAPTER 7
CONCLUSIONS AND RECOMMENDATIONS
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The increased incidence of methicillin resistance and multidrug resistance were
connected to the S. pseudintermedius. Given the few antibiotics available for therapy in
the veterinary world, new strategies for treating or preventing infection are essential.
Vaccine growth requires understanding the essence of immune reaction against S.
pseudintermedius infection.
Multiple S. aureus studies have shown that a successful vaccine can be one that can
boost both B-cells and T-cells with several distinct antigenic determinants. Given these
variables, mass spectrometry was evaluated for the secretome, surface-associated
proteins and IgG proteins from three kinds of representative sequences. From the
information, a key S. pseudintermedius virulence proteins were identified and
characterized.
Characterization of S. pseudintermedius SpsQ has provided information about the
immune evasive role of this protein and it is superantigenic effect on canine B cells. The
amino acids in the S. pseudintermedius SpsQ that are critical for Ig Fc and Fab regions
were identified, and a non-toxigenic form of the protein was produced and tested both in
vitro and in vivo as a potential vaccine candidate.
We described a unique pore-forming toxin from S. pseudintermedius.
The killing effect of recombinant S. pseudintermedius LukS-I and LukF-I on canine
polymorph nuclear leukocytes was determined. The cytotoxic effect occurred only when
the two recombinant proteins were combined. Engineered mutant versions of the twocomponent pore-forming leucocidins, produced through amino acids substitutions at
selected points, were not cytotoxic. Anti-Luk-I produced in dogs against attenuated
proteins reduced the cytotoxic effect of native S. pseudintermedius leukotoxin, which
highlights the importance of Luk-I as a promising component in a vaccine against
canine S. pseudintermedius infections.
S. pseudintermedius exotoxin provisionally named SpEX was identified. This exoprotein
binds to complement component C5, prevents complement mediated lysis of sensitized
bovine red blood cells, kills polymorphonuclear leukocytes and monocytes and inhibits
neutrophil migration at sub-lethal concentrations. A mutant version of SpEX, produced
through amino acid substitution at selected positions, had diminished cytotoxicity. Anti123

SpEX produced in dogs reduced the inhibitory effect of native SpEX on canine
neutrophil migration and protected immune cells from the toxic effects of the native
recombinant protein.
We identified a putative 5′-nucleotidase provisionally named SpAdsA, an S.
pseudintermedius cell- wall protein encoded by SpAdsA. SpAdsA catalyze the
dephosphorylation of adenosine mono- and triphosphates producing adenosine that
suppresses phagocytosis and facilitates bacterial survival. Attenuation of this enzyme
with critical amino acid substitutions nearly eliminated its hydrolytic activity. Antibody
against SpAdsA-M was developed in clinically healthy dogs and the neutralizing effect
of those antibodies was evaluated.
These results suggest that attenuated S. pseudintermedius proteins may be an
important candidate for inclusion in a vaccine composite against S. pseudintermedius
infections. This work characterized the critical domains and the essential amino acids
sites within a key of S. pseudintermedius virulence proteins and that can utilize to
design a chimeric protein consisting of a cocktail of functional and nontoxic domains
from the identified S. pseudintermedius virulence proteins.
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